1
|
Kawaguchi K, Maeshima Y, Ishiguro H, Yamagami K, Takahara S, Suwa H, Torii M, Nagai S, Sagara Y, Tsuji W, Yamashiro H, Kotake T, Fukuda S, Saito K, Yamamoto Y, Kataoka M, Himoto Y, Yonezawa A, Fukui Y, Nakamura Y, Li W, Tanaka S, Morita S, Toi M. Abstract P2-26-07: Alteration of gut microbiota signatures and its association with diarrhea during abemaciclib treatment: A multicenter prospective cohort study (KBCRN-A002 study). Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p2-26-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Background: Abemaciclib is a selective CDK4 and CDK6 inhibitor with demonstrated efficacy in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The most common adverse event across previous trials was early-onset diarrhea, affecting the patients’ quality of life and necessitating dose reductions. However, the exact mechanism for the lower rate of diarrhea in the other CDK4 and CDK6 inhibitors compared with abemaciclib is unknown. Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with the anti-tumor response; however, reported microbial signatures associated with adverse events by anti-cancer agent are inconsistent. To determine the underlying mechanism, we evaluated the correlation between diarrhea with abemaciclib and microbiota signatures in a metastatic breast cancer cohort.
Methods: The KBCRN-A002 study is a multicenter, prospective cohort study, which aims to evaluate the association between gut microbiota signatures and abemaciclib-induced diarrhea in breast cancer patients. Patients with metastatic breast cancer who were receiving abemaciclib were eligible. The primary objective of this study is the correlation between diarrhea and the microbiota signatures and immune profile. Incidence and severity of diarrhea were evaluated by the Bristol stool scale at baseline, from day 1 to day 14, and at day 90 of treatment. Stool samples were collected at baseline and at day 90 after the start of abemaciclib treatment. The gut microbiota signature was evaluated by 16S rRNA analysis. Blood samples were collected at baseline and at days 14 and 90 after starting abemaciclib to evaluate the correlation between the gut microbiota signatures and the systemic immune profile in peripheral blood mononuclear cells (PBMCs). The immune profile was evaluated by mass cytometry, multi-plex cytokines assay, and RNA-sequencing of bulk PBMCs. We characterized the gut microbiota signatures, immune cell composition, immune cell signature, comprehensive cytokines, and severity of diarrhea in all patients.
Results: We analyzed 39 patients, 77 stool samples, and 117 blood samples. In the preplanned interim analysis, among the 39 patients, 90% experienced diarrhea. Depleted gut microbiome α-diversity was positively associated with abemaciclib treatment and the severity of diarrhea. The relative abundances of 10 intestinal bacteria species increased and those of 18 intestinal bacteria decreased significantly after abemaciclib treatment, including bacteria known to be involved in diarrhea severity and anti-tumor immunity, such as Faecalibacterium (Table). The immune cell and cytokine profiles in PBMCs were also associated with the gut microbiota signatures.
Conclusions: Gut microbiota signatures are associated with abemaciclib-induced diarrhea and the immune profile in metastatic breast cancer patients. These findings can help to elucidate the mechanism of diarrhea caused by abemaciclib and offer strategies for its management and prevention.
Intestinal Microbiota Altered by Abemaciclib
Citation Format: Kosuke Kawaguchi, Yurina Maeshima, Hiroshi Ishiguro, Kazuhiko Yamagami, Sachiko Takahara, Hirofumi Suwa, Masae Torii, Shigenori Nagai, Yasuaki Sagara, Wakako Tsuji, Hiroyasu Yamashiro, Takeshi Kotake, Shinji Fukuda, Kuniaki Saito, Yasuko Yamamoto, Masako Kataoka, Yuki Himoto, Atsushi Yonezawa, Yukiko Fukui, Yuki Nakamura, Wei Li, Sunao Tanaka, Satoshi Morita, Masakazu Toi. Alteration of gut microbiota signatures and its association with diarrhea during abemaciclib treatment: A multicenter prospective cohort study (KBCRN-A002 study) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P2-26-07.
Collapse
Affiliation(s)
| | - Yurina Maeshima
- 2Department of Breast Surgery, Kyoto University Hospital, Graduate School of Medicine
| | - Hiroshi Ishiguro
- 3Saitama Medical University International Medical Center, Saitama, Japan
| | | | - Sachiko Takahara
- 5Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Hirofumi Suwa
- 6Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | - Masae Torii
- 7Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | - Yukiko Fukui
- 19Department of Breast Surgery, Kyoto University Hospital, Graduate School of Medicine, Kyoto, Japan
| | - Yuki Nakamura
- 20Department of Breast Surgery, Kyoto University Hospital, Graduate School of Medicine
| | - Wei Li
- 21Department of Breast Surgery, Kyoto University Hospital, Graduate School of Medicine
| | - Sunao Tanaka
- 22Department of Breast Surgery, Kyoto University Hospital, Graduate School of Medicine
| | - Satoshi Morita
- 23Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Masakazu Toi
- 24Department of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
| |
Collapse
|
2
|
Kawaguchi-Sakita N, Senda N, Inagaki-Kawata Y, Murakami H, Honda S, Yamada T, Kataoka Y, Takahara S, Tsuyuki S, Yamagami K, Moriguchi Y, Torii M, Kato T, Suwa H, Tsuji W, Suzuki E, Yamauchi A, Okamura R, Kosugi S, Toi M. Abstract P2-05-02: Potential Empowerment and risk of Genetic Counseling with Genetic Breast cancer risk assessment in Personalized Health Care: Prospective Cohort Study using Genetic Counseling Outcome Scale (GCOS-24). Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-p2-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
[Introduction] Personalized health care is recommended for the prevention and early detection of breast cancer. Advances in technology have made it possible to estimate genetic risk, PGV (pathogenic/likely-pathogenic germline variant) or PRS (polygenic risk score), in practice. However, linkage after risk assessment to personalized health care is still developing. One of the issues is how to tell the result especially in case of newly diagnosed PGV after Genetic Panel Testing or PRS. In this study, we evaluated genetic counseling (GC) using an established patient-reported outcome measure for clinical genetics services scale (Genetic Counseling Outcome Scale24 (GCOS24)) at genetic counseling for disclosure the results of the previous study, and examined the association with management after GC. [Method] We performed targeted sequencing for 11 breast cancer-related genes using peripheral blood DNA from 1995 female breast cancer patients. Of 1995 cases, 101 patients were PGV carriers, who were candidates of this study. Participants were referred to the Clinical Genetics unit, Kyoto University Hospital from 10 institutions (January 2018-March 2022). GCOS24 and relating questionaries were asked before and after GC. GCOS24 is a scale consisting of 24 items that assess five factors: decision control, cognitive control, behavioral control, emotional regulation, and hope. (In light of the current status of hereditary breast cancer care in Japan, 23 items were used.) Each item is rated on a scale of 1-7 points, for a total score of 23-161. In addition, we reviewed medical records to evaluate the post-GC management. [Results] Of the 101 cases, 38 cases were enrolled. The reasons of 63 not-enrolled cases were: 30 cases without follow-up (deaths or transfer to another hospital), 11 cases already diagnosed in clinical practice, 18 cases that did not wish to know their results, and 4 cases whose hospital were developing for hereditary breast cancer care. Median age at the time of genetic GC was 55 (min-max 30-83) years. Details of PGV cases were: BRCA2 23 cases, BRCA1 2, PALB2 4, PTEN 3, TP53 3, ATM 1, CHEK2 1 and NF1 1. GCOS24 after GC were improved than before GC. (Average 99 (min-max 17-124) vs 114 (91-138), Mean difference 23.9, 95% Confidence intervals (CI) 29.6 to 18.3). Thirty patients (79%) had higher increase in scores than 10.3, which was the previously reported Minimum Clinically Important Difference (MCID) of this scale. In all items except 4 items (#6,11,13,21), GCOS24 after GC were significantly improved than before GC. In post-GC management, 8 patients received or planned RRSO (risk reducing salpingo-oophorectomy) among 25 BRCA1/2 cases. There was a case with dysplastic cells detected in the resected ovary. After GC, average of GCOS24 in RRSO cases was 120 (95% CI 110 to 129), while average of GCOS24 of other BRCA1/2 cases was 110 (95% CI 104 to 116). On the other hand, two patients stopped visiting to the hospital because of fear after GC. Average of GCOS24 of 15 junior-high/high school graduate cases were 111 (95% CI 105 to 117), while average of GCOS24 of 23 college graduate cases were 117 (95% CI 111 to 122). [Discussion] In patients diagnosed with hereditary breast cancer by genetic panel testing, GC worked well except for 4 items. These 4 items (#6,11,13,21) were related to emotion. This study revealed there was also a risk to reject surveillance due to fear, suggesting that it is necessary to provide psychological support in some cases. Although the limitation of this study is the small number of cases, GCOS24 were high in RRSO cases, suggesting that GC played an important role when proceeding with intervention. We believe that the findings are helpful for the future implementation of genetic panel testing or PRS testing in healthy subjects for personalized health care.
Citation Format: Nobuko Kawaguchi-Sakita, Noriko Senda, Yukiko Inagaki-Kawata, Hiromi Murakami, Sayaka Honda, Takahiro Yamada, Yuki Kataoka, Shoko Takahara, Shigeru Tsuyuki, Kazuhiko Yamagami, Yoshio Moriguchi, Masae Torii, Tatsushi Kato, Hirofumi Suwa, Wakako Tsuji, Eiji Suzuki, Akira Yamauchi, Ryuji Okamura, Shinji Kosugi, Masakazu Toi. Potential Empowerment and risk of Genetic Counseling with Genetic Breast cancer risk assessment in Personalized Health Care: Prospective Cohort Study using Genetic Counseling Outcome Scale (GCOS-24) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P2-05-02.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Masae Torii
- 12Japanese Red Cross Wakayama Medical Center, Wakayama, Wakayama, Japan
| | | | - Hirofumi Suwa
- 14Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan
| | | | | | | | | | | | - Masakazu Toi
- 20Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
3
|
Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Ogura N, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study. Breast Cancer 2022; 29:796-807. [PMID: 35460066 DOI: 10.1007/s12282-022-01357-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 04/03/2022] [Indexed: 11/02/2022]
Abstract
BACKGROUND The optimal positioning of eribulin treatment remains unclear. This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocrine-resistant advanced or metastatic breast cancer (AMBC) in the real-world clinical setting. METHODS This multi-institutional prospective cohort study enrolled patients with triple-negative AMBC or estrogen receptor-positive AMBC refractory to at least one previous endocrine therapy. The overall survival (OS) from the start of first-line (OS1) and second-line chemotherapy (OS2) was assessed. Data analysis included real-world chemotherapy sequences of first- to third-line chemotherapy regimens. The adjusted hazard ratio (HR) with 95% confidence interval (CI) for treatment regimen comparison was calculated using a stratified proportional hazards model. RESULTS Among 201 patients enrolled, 180 were included in the final analysis. Eribulin was administered as first- and second-line chemotherapy to 46 (26.6%) and 70 (47.9%) patients, respectively. Median OS1 and OS2 were 2.25 (95% CI 1.07-2.68) and 1.75 (95% CI, 1.28-2.45) years for first- and second-line eribulin, respectively. Oral 5-FU followed by eribulin had a numerically longer OS1 (2.84 years) than the other sequences. Among patients who proceeded to second-line or later chemotherapy, the median OS1 for those treated with anthracycline or taxane as first- or second-line (n = 98) was 2.56 years (95% CI 2.27-2.74), while it was 2.87 years (95% CI 2.20-4.32) for those who avoided anthracycline and taxane as first- and second-line (n = 48) (adjusted HR, 1.20; 95% CI 0.70-2.06). In the exploratory analysis, OS1 was 2.55 (95% CI 2.14-2.75) and 2.91 years (95% CI 2.61-4.32) for those aged < 65 and ≥ 65 years, respectively (adjusted HR of ≥ 65, 0.91; 95% CI 0.56-1.46). CONCLUSIONS Eribulin or oral 5-FU administration in first- and second-line chemotherapy without anthracycline/taxane was acceptable in the real-world setting. TRIAL REGISTRATION This study is registered with Clinical Trials.gov (NCT 02,551,263).
Collapse
Affiliation(s)
- Yuichiro Kikawa
- Department of Breast Surgery, Kansai Medical University, Hirakata-city, Osaka, 573-1191, Japan. .,Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe-city, Hyogo, 650-0047, Japan.
| | - Takeshi Kotake
- Department of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto-city, Kyoto, 606-8507, Japan.,Department of Breast Surgery, Kansai Electric Power Hospital, Osaka-city, Osaka, 553-0003, Japan
| | - Shigeru Tsuyuki
- Department of Breast Surgery, Osaka Red Cross Hospital, Osaka-city, Osaka, 543-8555, Japan
| | - Yookija Kang
- Department of Breast Surgery, Osaka Red Cross Hospital, Osaka-city, Osaka, 543-8555, Japan
| | - Sachiko Takahara
- Department of Breast Surgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka-city, Osaka, 530-8480, Japan
| | - Yuri Fujimoto
- Department of Breast Surgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka-city, Osaka, 530-8480, Japan
| | - Hiroyasu Yamashiro
- Department of Breast Surgery, Tenri Hospital, Tenri-city, Nara, 632-0018, Japan
| | | | - Masahiro Takada
- Department of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto-city, Kyoto, 606-8507, Japan
| | - Rie Yasuoka
- Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, 602-8566, Japan
| | - Katsuhiko Nakatsukasa
- Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, 602-8566, Japan
| | - Kazuhiko Yamagami
- Department of Breast Surgery, Shinko Hospital, Kobe-city, Hyogo, 651-0072, Japan
| | - Hirofumi Suwa
- Department of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki-city, Hyogo, 660-8550, Japan
| | - Toshitaka Okuno
- Department of Breast Surgery, Kobe City Nishi-Kobe Medical Center, Kobe-city, Hyogo, 651-2273, Japan
| | - Ichiro Nakayama
- Department of Breast Surgery, Kyoto Min-Iren Chuo Hospital, Kyoto-city, 616-8147, Japan
| | - Tatsushi Kato
- Department of Breast Surgery, Yamato Takada Municipal Hospital, Yamatotakada-city, Nara, 635-8501, Japan
| | - Nobuko Ogura
- Department of Breast Surgery, Kansai Electric Power Hospital, Osaka-city, Osaka, 553-0003, Japan
| | - Yoshio Moriguchi
- Department of Breast Surgery, Kyoto City Hospital, Kyoto-city, Kyoto, 604-8845, Japan
| | - Hiroshi Ishiguro
- Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka-city, Saitama, 350-1298, Japan
| | - Tatsuo Kagimura
- Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe-city, Hyogo, 650-0047, Japan
| | - Tetsuya Taguchi
- Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto-city, Kyoto, 602-8566, Japan
| | - Tomoharu Sugie
- Department of Breast Surgery, Kansai Medical University, Hirakata-city, Osaka, 573-1191, Japan
| | - Masakazu Toi
- Department of Breast Surgery, Kyoto University Graduate School of Medicine, Kyoto-city, Kyoto, 606-8507, Japan
| |
Collapse
|
4
|
Yuen S, Monzawa S, Gose A, Yanai S, Yata Y, Matsumoto H, Ichinose Y, Tashiro T, Yamagami K. Impact of background parenchymal enhancement levels on the diagnosis of contrast-enhanced digital mammography in evaluations of breast cancer: comparison with contrast-enhanced breast MRI. Breast Cancer 2022; 29:677-687. [DOI: 10.1007/s12282-022-01345-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 02/13/2022] [Indexed: 11/28/2022]
|
5
|
Yamaguchi T, Yamagami K. Burton's line: a sign of chronic lead poisoning. QJM 2021; 114:752. [PMID: 34264343 DOI: 10.1093/qjmed/hcab192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- T Yamaguchi
- Primary Care and Advanced Triage Section, Osaka City General Hospital, 2-13-22 Miyakojima-Hondori, Miyakojima-Ku, Osaka 534-0021, Japan
| | - K Yamagami
- Internal Medicine, Osaka City General Hospital, 2-13-22 Miyakojima-Hondori, Miyakojima-Ku, Osaka 534-0021, Japan
| |
Collapse
|
6
|
Yamagami K, Nomura A, Kometani M, Shimojima M, Sakata K, Usui S, Furukawa K, Takamura M, Okajima M, Watanabe K, Yoneda T. Early detection of exacerbation of the severe acute respiratory syndrome coronavirus 2 infection using Fitbit (DEXTERITY pilot study). Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Some patients with coronavirus disease 2019 (COVID-19) experienced sudden death because of sudden symptom deterioration. Thus, an alarm system that could detect early signs of COVID-19 exacerbation beforehand, to prevent serious illness or death of patients while receiving outpatient treatment at home or in hotels is necessary. Here, we tested whether estimated oxygen variations (EOV), a relative physiological scale that represents users' blood oxygen saturation level during sleep measured by Fitbit, predicted COVID-19 symptom exacerbation. Study period was from August to November 2020. We enrolled 23 COVID-19 patients diagnosed by SARS-CoV-2 polymerase chain reaction-positive (mean age ± standard deviation, 50.9±20 years; 70% female), let each patient wore the Fitbit for 30 days; COVID-19 symptoms were exacerbated in 6 (26%). High EOV signal (a patient's oxygen level exhibits significant dip and recovery within the index period) had 80% sensitivity before symptom exacerbations, whereas resting heart rate signal only had 50% sensitivity. Coincidental obstructive sleep apnea syndrome confirmed by polysomnography was detected in a patient by consistently high EOV signals. This pilot study successfully detected early COVID-19 symptoms exacerbation by measuring EOV and may help to identify early signs of COVID-19 exacerbation.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): The investigational device used in this study, Fitbit Charge 3, was provided by Fitbit Japan. Summary of high EOV signals and eventsThe clinical course of COVID-19
Collapse
Affiliation(s)
- K Yamagami
- Kanazawa University Hospital, Kanazawa, Japan
| | - A Nomura
- Kanazawa University Hospital, Kanazawa, Japan
| | - M Kometani
- Kanazawa University Graduate School of Medicine, Department of Health Promotion and Medicine of the Future, Kanazawa, Japan
| | - M Shimojima
- Kanazawa University Hospital, Kanazawa, Japan
| | - K Sakata
- Kanazawa University Hospital, Kanazawa, Japan
| | - S Usui
- Kanazawa University Hospital, Kanazawa, Japan
| | - K Furukawa
- Health Care Center, Japan Advanced Institute of Science and Technology, Kanazawa, Japan
| | - M Takamura
- Kanazawa University Hospital, Kanazawa, Japan
| | - M Okajima
- Kanazawa University Hospital, Intensive Care Unit, Kanazawa, Japan
| | - K Watanabe
- JCHO Kanazawa Hospital, Kaznazawa, Japan
| | - T Yoneda
- Kanazawa University Graduate School of Medicine, Department of Health Promotion and Medicine of the Future, Kanazawa, Japan
| |
Collapse
|
7
|
Senda N, Kawaguchi-Sakita N, Kawashima M, Inagaki-Kawata Y, Yoshida K, Takada M, Kataoka M, Torii M, Nishimura T, Kawaguchi K, Suzuki E, Kataoka Y, Matsumoto Y, Yoshibayashi H, Yamagami K, Tsuyuki S, Takahara S, Yamauchi A, Shinkura N, Kato H, Moriguchi Y, Okamura R, Kan N, Suwa H, Sakata S, Mashima S, Yotsumoto F, Tachibana T, Tanaka M, Togashi K, Haga H, Yamada T, Kosugi S, Inamoto T, Sugimoto M, Ogawa S, Toi M. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. Cancer Sci 2021; 112:3338-3348. [PMID: 34036661 PMCID: PMC8353892 DOI: 10.1111/cas.14986] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 04/30/2021] [Accepted: 05/06/2021] [Indexed: 12/19/2022] Open
Abstract
Predicting pathogenic germline variants (PGVs) in breast cancer patients is important for selecting optimal therapeutics and implementing risk reduction strategies. However, PGV risk factors and the performance of prediction methods in the Japanese population remain unclear. We investigated clinicopathological risk factors using the Tyrer‐Cuzick (TC) breast cancer risk evaluation tool to predict BRCA PGVs in unselected Japanese breast cancer patients (n = 1,995). Eleven breast cancer susceptibility genes were analyzed using target‐capture sequencing in a previous study; the PGV prevalence in BRCA1, BRCA2, and PALB2 was 0.75%, 3.1%, and 0.45%, respectively. Significant associations were found between the presence of BRCA PGVs and early disease onset, number of familial cancer cases (up to third‐degree relatives), triple‐negative breast cancer patients under the age of 60, and ovarian cancer history (all P < .0001). In total, 816 patients (40.9%) satisfied the National Comprehensive Cancer Network (NCCN) guidelines for recommending multigene testing. The sensitivity and specificity of the NCCN criteria for discriminating PGV carriers from noncarriers were 71.3% and 60.7%, respectively. The TC model showed good discrimination for predicting BRCA PGVs (area under the curve, 0.75; 95% confidence interval, 0.69‐0.81). Furthermore, use of the TC model with an optimized cutoff of TC score ≥0.16% in addition to the NCCN guidelines improved the predictive efficiency for high‐risk groups (sensitivity, 77.2%; specificity, 54.8%; about 11 genes). Given the influence of ethnic differences on prediction, we consider that further studies are warranted to elucidate the role of environmental and genetic factors for realizing precise prediction.
Collapse
Affiliation(s)
- Noriko Senda
- Department of Breast Surgery, Kyoto University, Kyoto, Japan
| | | | | | | | - Kenichi Yoshida
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | - Masahiro Takada
- Department of Breast Surgery, Kyoto University, Kyoto, Japan
| | - Masako Kataoka
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University, Kyoto, Japan
| | - Masae Torii
- Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| | | | | | - Eiji Suzuki
- Department of Breast Surgery, Kyoto University, Kyoto, Japan
| | - Yuki Kataoka
- Department of Healthcare Epidemiology, School of Public Health, in the Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | | | - Hiroshi Yoshibayashi
- Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| | - Kazuhiko Yamagami
- Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| | - Shigeru Tsuyuki
- Department of Breast Surgery, Osaka Red Cross Hospital, Osaka, Japan
| | | | - Akira Yamauchi
- Department of Breast Surgery, Kitano Hospital, Osaka, Japan
| | - Nobuhiko Shinkura
- Department of Surgery, Ijinkai Takeda General Hospital, Kyoto, Japan
| | - Hironori Kato
- Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, Japan
| | | | - Ryuji Okamura
- Department of Breast Surgery, Yamatotakada Municipal Hospital, Yamatotakada, Japan
| | | | - Hirofumi Suwa
- Department of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | - Shingo Sakata
- Department of Breast Surgery, Rakuwakai Otowa Hospital, Kyoto, Japan
| | - Susumu Mashima
- Department of Surgery, Japan Community Health Care Organization, Yamato Koriyama Hospital, Yamato Koriyama, Japan
| | - Fumiaki Yotsumoto
- Department of Breast Surgery, Shiga General Hospital, Moriyama, Japan
| | | | - Mitsuru Tanaka
- Department of Surgery, Hirakata Kohsai Hospital, Hirakata, Japan
| | - Kaori Togashi
- Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University, Kyoto, Japan
| | - Hironori Haga
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
| | - Takahiro Yamada
- Department of Medical Ethics/Medical Genetics, Kyoto University, Kyoto, Japan
| | - Shinji Kosugi
- Department of Medical Ethics/Medical Genetics, Kyoto University, Kyoto, Japan
| | - Takashi Inamoto
- Faculty of Health Care, Tenri Health Care University, Tenri, Japan
| | - Masahiro Sugimoto
- Health Promotion and Preemptive Medicine, Research and Development Center for Minimally Invasive Therapies, Tokyo Medical University, Tokyo, Japan
| | - Seishi Ogawa
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | - Masakazu Toi
- Department of Breast Surgery, Kyoto University, Kyoto, Japan
| |
Collapse
|
8
|
Miki M, Takao S, Konishi M, Shigeoka Y, Miyashita M, Suwa H, Miyoshi Y, Hirokaga K, Okuno T, Yamagami K, Imamura M, Murase K, Yanai A, Tanino H. Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13). Anticancer Res 2021; 41:3121-3126. [PMID: 34083305 DOI: 10.21873/anticanres.15096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 05/19/2021] [Accepted: 05/20/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM S-1, a 5-fluorouracil(5-FU) oral anti-cancer drug, has been traditionally used with a schedule of 4-week oral administration followed by 2-week rest for breast cancer treatment. We, herein, aimed to investigate the clinical efficacy and safety of a schedule of 2-week oral administration followed by 1-week rest for patients with metastatic breast cancer. PATIENTS AND METHODS We enrolled patients with HER2-negative metastatic breast cancer who had not received prior chemotherapy. S-1 was administered consecutively for 2-weeks followed by a 1-week rest. RESULTS Between September 1, 2013 and August 31, 2016, 32 patients were enrolled. The median follow-up time was 32.1 months. The median progression-free survival (PFS) was 9.4 months. Overall survival (OS) was 41.0 months, time to treatment failure (TTF) was 7.8 months, response rate (RR) was 31.3%, and disease control rate (DCR) was 78.1%. The incidence of grade 3 side-effects was not high. CONCLUSION The 3-week schedule of S-1 can be considered useful as a treatment for patients with metastatic breast cancer, helping in maintaining a high quality of life.
Collapse
Affiliation(s)
- Mayuko Miki
- Department of Breast Surgery, Kobe University Hospital, Kobe, Japan; .,Department of Breast Surgery, Hyogo Cancer Center, Hyogo, Japan
| | - Shintaro Takao
- Department of Breast Surgery, Hyogo Cancer Center, Hyogo, Japan
| | - Muneharu Konishi
- Department of Breast Surgery, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan
| | - Yasushi Shigeoka
- Department of Oncology, Yodogawa Christian Hospital, Osaka, Japan
| | | | - Hirofumi Suwa
- Department of Breast Surgery, Hyogo Prefectural Amagasaki Medical Center, Hyogo, Japan
| | - Yasuo Miyoshi
- Department of Breast Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Koichi Hirokaga
- Department of Breast Surgery, Hyogo Cancer Center, Hyogo, Japan
| | - Toshitaka Okuno
- Department of Breast Surgery, Kobe City Nishi-kobe Medical Center, Kobe, Japan
| | | | - Michiko Imamura
- Department of Breast Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Keiko Murase
- Department of Breast Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Ayako Yanai
- Department of Breast Surgery, Hyogo College of Medicine, Hyogo, Japan
| | - Hirokazu Tanino
- Department of Breast Surgery, Kobe University Hospital, Kobe, Japan
| |
Collapse
|
9
|
Futamura M, Oba M, Masuda N, Bando H, Okada M, Yamamoto Y, Kin T, Saeki T, Nagashima T, Kuwayama T, Toh U, Hirano A, Inokuchi M, Yamagami K, Mizuno Y, Kojima Y, Nakayama T, Yasojima H, Ohno S. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). Breast Cancer 2021; 28:1023-1037. [PMID: 33811599 PMCID: PMC8354972 DOI: 10.1007/s12282-021-01238-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Accepted: 03/08/2021] [Indexed: 11/26/2022]
Abstract
Background Nanoparticle albumin-bound paclitaxel (nab-PTX), a novel taxane formulation, was developed to avoid cremophor/ethanol-associated toxicities including peripheral neuropathy and hypersensitivity. At least 35 phase II studies using combined nab-PTX and anthracycline in neoadjuvant settings are registered in Japan. We analyzed the efficacy and safety of nab-PTX based on patient characteristics in these studies. Methods We conducted a meta-analysis using individual patient data (IPD) to investigate the average efficacy of nab-PTX-containing regimens as neoadjuvant chemotherapy for operable breast cancer. IPD were provided by principal investigators who agreed to participate. The primary endpoint was pathological complete response (pCR) rate of each breast cancer subtype. Results We analyzed the data of 16 studies involving 753 patients. The overall crude frequencies of pCR (ypT0 ypN0, ypT0/is ypN0, and ypT0/is ypNX) were 18.1, 26.0, and 28.6%, respectively. Specifically, the frequencies were 6.7, 10.2, and 13.4% for luminal (n = 343); 40.5, 63.5, and 68.9% for human epidermal growth factor receptor 2 (HER2)-rich, (n = 74); 21.9, 40.6, and 42.7% for luminal/HER2 (n = 96); and 26.3, 31.5, and 32.3% for triple-negative breast cancers (TNBC) (n = 232). The multivariate analyses indicated that HER2 positivity, TNBC, high Ki-67, high nuclear grade, and weekly nab-PTX administration were significantly associated with the pCR. The proportion of hematological toxicities (neutropenia (39.7%) and leukopenia (22.5%)), peripheral sensory neuropathy (9.7%), myalgia (5.7%), and arthralgia (4.7%) was higher than grade 3 adverse events, but most patients recovered. Conclusions Nab-PTX is a safe and acceptable chemotherapeutic agent in neoadjuvant settings, particularly for aggressive cancers. UMIN-CTR#: UMIN000028774 Supplementary Information The online version contains supplementary material available at 10.1007/s12282-021-01238-9.
Collapse
Affiliation(s)
- Manabu Futamura
- Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.
| | - Mari Oba
- Department of Medical Statistics, Toho University, Tokyo, 143-8540, Japan
| | - Norikazu Masuda
- Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, 540-0006, Japan
| | - Hiroko Bando
- Department of Breast-Thyroid-Endocrine Surgery, Tsukuba University, Tsukuba, 305-8576, Japan
| | - Morihito Okada
- Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, 734-8553, Japan
| | - Yutaka Yamamoto
- Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan
| | - Takanori Kin
- Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, 730-8518, Japan
| | - Toshiaki Saeki
- Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, 350-1298, Japan
| | - Takeshi Nagashima
- Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, 260-8677, Japan
| | - Takashi Kuwayama
- Division of Breast Surgical Oncology, Showa University, Tokyo, 142-8666, Japan
| | - Uhi Toh
- Department of Surgery, Kurume University School of Medicine, Kurume, 830-0011, Japan
| | - Akira Hirano
- Department of Breast Surgery, Medical Center East, Tokyo Women's Medical University, Tokyo, 116-8567, Japan
| | - Masafumi Inokuchi
- Department of Breast and Endocrine Surgery, Kanazawa Medical University, Ishikawa, 920-0293, Japan
| | - Kazuhiko Yamagami
- Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, 651-0072, Japan
| | - Yutaka Mizuno
- Department of Breast Surgery, Yokkaichi Municipal Hospital, Yokkaichi, 510-8567, Japan
| | - Yasuyuki Kojima
- Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, Kawasaki, 216-8511, Japan
| | - Takahiro Nakayama
- Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, 541-8567, Japan
| | - Hiroyuki Yasojima
- Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, 540-0006, Japan
| | - Shinji Ohno
- Breast Oncology Center, Cancer Institute Hospital, Tokyo, 135-0063, Japan
| |
Collapse
|
10
|
Fujimoto Y, Kikawa Y, Kotake T, Tsuyuki S, Takahara S, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Ogura N, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. Abstract PS13-31: Prospective observational study to explore the effectiveness of eribulin as first- or second- line chemotherapy in patients with HER2-negative hormone-resistant advanced or metastatic breast cancer (KBCRN A001: E-SPEC study). Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ps13-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BackgroundEribulin (E) is a chemotherapeutic drug that prolongs overall survival (OS) of patients with HER2-negative advanced or metastatic breast cancer (AMBC), mainly in multi-line chemotherapy (ChT) or later. However, the effectiveness and optimal scheduling of E remain unclear. We prospectively investigated the impact of E use in 1st- and 2nd-line ChT (early E) for patients with endocrine-resistant AMBC.
Methods In this multi-institutional prospective cohort study, we registered patients with hormone receptor-positive AMBC who relapsed during or within 6 months after ending adjuvant endocrine therapy, were refractory to at least one previous endocrine therapy, or patients with triple negative AMBC. The endpoints were 1st-line OS (OS1), 2nd-line OS (OS2), and 3rd-line OS (OS3), defined as the time from the start of treatment to death. In addition, the time from the start of 1st-line ChT to death was also analyzed for 2nd-line and 3rd-line ChT groups. In addition to E therapy, oral FU-based therapies (FU) and anthracycline or taxane-based therapies (A/T) were also analyzed (ClinicalTrial.gov number, NCT02551263).
Results Between June 2015 and July 2017, a total of 201 patients were enrolled, and full analysis was conducted for 180 patients. The median OS1, OS2, and OS3 of all patients was 2.69, 1.74, and 1.13 years, respectively. Major patient characteristics are described in the Table. Concurrent or maintenance endocrine therapy was used by 14.9%, 31.6%, and 12.9% of patients receiving E, FU and A/T in 1st-line ChT, respectively. The median OS of patients using E was OS1: 2.25 years (N=47), OS2: 1.75 years (N=70) and OS3: 0.94 years (N=16). The median OS of patients using A/T was OS1: 2.60 years (N=70), OS2: 1.69 years (N=44) and OS3: 0.96 years (N=49). The median OS of patients using FU was OS1: 3.49 years (N=57), OS2: 2.33 years (N=27), and OS3: 1.45 years (N=24). The time from the start of 1st-line ChT to death was 2.58 and 3.18 years among patients who received E in 2nd- and 3rd-line ChT, respectively. Multivariate analysis of patients who used 1st-line and 2nd-line E demonstrated that higher LDH (≥300) (HR 3.50, 95% CI 1.78-6.73; p<0.001), brain metastasis (HR 2.64, 95% CI 1.02-6.83; p=0.045) and smoker (HR 2.33, 95% CI 1.20-4.53; p=0.013) were associated with shorter OS. Overall, OS data for E were comparable to those for A/T. While OS tended to be better for FU, patient characteristics for 1st-line ChT showed that FU was often used for patients with less aggressive AMBC. We also present data on second progression-free survival and new metastasis-free survival, prognostic factor analysis and prognostic factor-adjusted comparison, and predictive factor analysis for early E.
Conclusions This prospective observational study of AMBC patients showed that E and A/T had similar survival outcomes in each treatment line. While FU led to relatively longer survival, it was often used for patients with less aggressive AMBC. Analysis data on survival outcomes will also be presented.
Patient characteristics according to 1st-line therapyE (n=47)Oral FU based (n=57)A/T based (n=70)Median age (IQR)61(54-71)64(51-68)59(48-66)Triple negative, n (%)15(31.9)11(19.3)23(32.9)Disease-free interval, n (%)<2 years15(31.9)9(15.8)12(17.1)2-5 years12(25.5)18(31.6)15(21.4)5-8 years4(8.5)9(15.8)9(12.9)>8years3(6.4)10(17.5)8(11.4)Stage49(19.1)9(15.8)23(32.9)(neo) Adjuvant chemotherapy, n (%)30(63.8)36(63.2)32(45.7)Metastatic sites at 1st-line ChT, n (%)Liver16(34.0)12(21.1)22(31.4)Lung15(31.9)17(29.8)25(35.7)Bone24(51.1)27(47.3)36(51.4)Brain6(12.8)1(1.8)2(2.9)
Citation Format: Yuri Fujimoto, Yuichiro Kikawa, Takeshi Kotake, Shigeru Tsuyuki, Sachiko Takahara, Hiroyasu Yamashiro, Hiroshi Yoshibayashi, Masahiro Takada, Rie Yasuoka, Kazuhiko Yamagami, Hirofumi Suwa, Toshitaka Okuno, Ichiro Nakayama, Tatsuji Kato, Nobuko Ogura, Yoshio Moriguchi, Hiroshi Ishiguro, Tatsuo Kagimura, Tetsuya Taguchi, Tomoharu Sugie, Masakazu Toi. Prospective observational study to explore the effectiveness of eribulin as first- or second- line chemotherapy in patients with HER2-negative hormone-resistant advanced or metastatic breast cancer (KBCRN A001: E-SPEC study) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS13-31.
Collapse
Affiliation(s)
- Yuri Fujimoto
- 1Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Yuichiro Kikawa
- 2Kansai Medical University Hospital / Kobe City Medical Center General Hospital, Osaka, Japan
| | - Takeshi Kotake
- 3Kyoto University Hospital Breast Surgery Department, Kyoto, Japan
| | | | - Sachiko Takahara
- 1Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | | | | | - Masahiro Takada
- 3Kyoto University Hospital Breast Surgery Department, Kyoto, Japan
| | - Rie Yasuoka
- 7Kyoto Prefectural University of Medicine, Kyoto, Japan
| | | | - Hirofumi Suwa
- 9Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | | | | | - Tatsuji Kato
- 12Yamato Takada Municipal Hospital, Yamatotakada, Japan
| | | | | | - Hiroshi Ishiguro
- 15International University of Health and Welfare Hospital Medical Oncology, Narita, Japan
| | - Tatsuo Kagimura
- 16Translational Research Center for Medical Innovation, Kobe, Japan
| | | | | | - Masakazu Toi
- 3Kyoto University Hospital Breast Surgery Department, Kyoto, Japan
| |
Collapse
|
11
|
Odan N, Kikawa Y, Matsumoto H, Minohata J, Suwa H, Hashimoto T, Okuno T, Miyashita M, Saito M, Yamagami K, Takao S. Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan-The KBCOG-14 Study. Breast Cancer (Auckl) 2020; 14:1178223420983843. [PMID: 33447040 PMCID: PMC7780165 DOI: 10.1177/1178223420983843] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Accepted: 12/07/2020] [Indexed: 01/02/2023]
Abstract
Background Clinical studies have shown that palbociclib improves progression-free survival in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) patients with advanced breast cancer (ABC). However, there are insufficient data on its use in a real-world setting in Japan. The aim of this study was to investigate the effectiveness, predictive factors, and safety of palbociclib among Japanese patients in routine clinical practice. Methods Between December 1, 2017, and April 30, 2019, we recruited patients from 9 hospitals and retrospectively evaluated the data on HR+/HER2- patients with ABC who received palbociclib for at least 1 week. The correlation between time-to-treatment discontinuation (TTD) and clinical background was investigated via univariate and multivariate analyses using Cox hazards models. Results A total of 177 women were available for analysis. Of these patients, 58 (33%) patients were treated with palbociclib with an aromatase inhibitor and 117 (66%) patients were treated with palbociclib and a selective estrogen receptor degrader. Approximately three-fourths of the patients (n = 130, 73%) received palbociclib as third- or later-line therapy. One-third of the patients had 3 or more metastatic sites (n = 59, 33%), and one-third of the patients had liver metastasis (n = 59, 33%). The median follow-up duration at the time of data cutoff was 8.9 months, the median TTD was 6.3 months, and the median overall survival was not reached. Liver metastasis (hazard ratio [HR]: 1.54 [95% confidence interval {CI}: 1.03-2.27]), high serum lactate dehydrogenase (LDH) level (>300 U/L) (HR: 2.58 [95% CI: 1.49-4.26]), and high neutrophil-to-lymphocyte ratio (NLR) (⩾3.0) (HR: 1.76 [95% CI: 1.13-2.69]) were significantly associated with shorter TTD. The most common hematologic adverse event was neutropenia, which occurred in 93% of the patients. Conclusion Based on the results of the pivotal phase 3 trials, the median TTD recorded in this study was shorter than expected. Our results suggest that liver metastasis, serum LDH level, and NLR may be predictive factors for HR+/HER2- ABC treatment outcomes.
Collapse
Affiliation(s)
- Nina Odan
- Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.,Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan.,Department of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | - Yuichiro Kikawa
- Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.,Department of Breast Surgery, Kansai Medical University Hospital, Hirakata, Japan
| | - Hajime Matsumoto
- Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| | - Junya Minohata
- Department of Breast Surgery, Yodogawa Christian Hospital, Osaka, Japan
| | - Hirofumi Suwa
- Department of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | | | - Toshitaka Okuno
- Department of Breast Surgery, Kobe City Nishi-Kobe Medical Center, Kobe, Japan
| | | | - Masaru Saito
- Department of Breast Surgery, Ikawadani Hospital, Kobe, Japan
| | - Kazuhiko Yamagami
- Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| | - Shintaro Takao
- Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan
| |
Collapse
|
12
|
Kang Y, Kikawa Y, Kotake T, Tsuyuki S, Takahara S, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. 52P Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, Shiraishi Y, Chiba K, Kataoka Y, Torii M, Yoshibayashi H, Yamagami K, Okamura R, Moriguchi Y, Kato H, Tsuyuki S, Yamauchi A, Suwa H, Inamoto T, Miyano S, Ogawa S, Toi M. Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. Commun Biol 2020; 3:578. [PMID: 33067557 PMCID: PMC7567851 DOI: 10.1038/s42003-020-01301-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Accepted: 09/15/2020] [Indexed: 12/24/2022] Open
Abstract
The genetic and clinical characteristics of breast tumors with germline variants, including their association with biallelic inactivation through loss-of-heterozygosity (LOH) and second somatic mutations, remain elusive. We analyzed germline variants of 11 breast cancer susceptibility genes for 1,995 Japanese breast cancer patients, and identified 101 (5.1%) pathogenic variants, including 62 BRCA2 and 15 BRCA1 mutations. Genetic analysis of 64 BRCA1/2-mutated tumors including TCGA dataset tumors, revealed an association of biallelic inactivation with more extensive deletions, copy neutral LOH, gain with LOH and younger onset. Strikingly, TP53 and RB1 mutations were frequently observed in BRCA1- (94%) and BRCA2- (9.7%) mutated tumors with biallelic inactivation. Inactivation of TP53 and RB1 together with BRCA1 and BRCA2, respectively, involved LOH of chromosomes 17 and 13. Notably, BRCA1/2 tumors without biallelic inactivation were indistinguishable from those without germline variants. Our study highlights the heterogeneity and unique clonal selection pattern in breast cancers with germline variants. Yukiko Inagaki-Kawata et al. report an analysis of germline variants in breast cancer susceptibility genes in 1,995 Japanese breast cancer patients. They find that 5.1% of the patients carry germline variants in cancer-linked genes and investigate the characteristics of patients with germline mutations in BRCA1/2.
Collapse
Affiliation(s)
- Yukiko Inagaki-Kawata
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.,Department of Breast Surgery, Kyoto University, Kyoto, Japan
| | - Kenichi Yoshida
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | | | | | - Tomomi Nishimura
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.,Department of Breast Surgery, Kyoto University, Kyoto, Japan
| | - Noriko Senda
- Department of Breast Surgery, Kyoto University, Kyoto, Japan
| | - Yusuke Shiozawa
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | - Yasuhide Takeuchi
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.,Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.,Department of Diagnostic Pathology, Kyoto University, Kyoto, Japan
| | - Yoshikage Inoue
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | - Aiko Sato-Otsubo
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | - Yoichi Fujii
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | - Yasuhito Nannya
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan
| | - Eiji Suzuki
- Department of Breast Surgery, Kyoto University, Kyoto, Japan
| | - Masahiro Takada
- Department of Breast Surgery, Kyoto University, Kyoto, Japan
| | - Hiroko Tanaka
- Laboratory of Sequence Analysis, Human Genome Centre, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Yuichi Shiraishi
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Kenichi Chiba
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Yuki Kataoka
- Hospital Care Research Unit/Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | - Masae Torii
- Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| | - Hiroshi Yoshibayashi
- Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| | | | - Ryuji Okamura
- Department of Breast Surgery, Yamatotakada Municipal Hospital, Yamatotakada, Japan
| | | | - Hironori Kato
- Department of Breast Surgery, Kobe City Medical Center General Hospital, Kobe, Japan
| | - Shigeru Tsuyuki
- Department of Breast Surgery, Osaka Red Cross Hospital, Osaka, Japan
| | - Akira Yamauchi
- Department of Breast Surgery, Kitano Hospital, Osaka, Japan
| | - Hirofumi Suwa
- Department of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | | | - Satoru Miyano
- Laboratory of Sequence Analysis, Human Genome Centre, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.,Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Seishi Ogawa
- Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan. .,Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan. .,Department of Medicine, Centre for Haematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
| | - Masakazu Toi
- Department of Breast Surgery, Kyoto University, Kyoto, Japan.
| |
Collapse
|
14
|
Yuen S, Monzawa S, Yanai S, Matsumoto H, Yata Y, Ichinose Y, Deai T, Hashimoto T, Tashiro T, Yamagami K. The association between MRI findings and breast cancer subtypes: focused on the combination patterns on diffusion-weighted and T2-weighted images. Breast Cancer 2020; 27:1029-1037. [PMID: 32377938 DOI: 10.1007/s12282-020-01105-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2019] [Accepted: 04/28/2020] [Indexed: 01/06/2023]
Abstract
PURPOSE To assess morphology on diffusion-weighted imaging (DWI) and intratumoral signal intensity (SI) on T2-weighted images (T2WI) of breast carcinomas, and to evaluate the association between the combined DWI and T2WI findings and breast cancer subtypes. METHODS Two hundred and eighty breast cancer patients who underwent breast MRI prior to therapy were included in this retrospective study. All had invasive carcinomas, which were classified into five subtypes: Luminal A-like (n = 149), Luminal B-like (n = 63), Hormone receptor-positive HER2 (n = 31), Hormone receptor-negative HER2 (n = 13), or Triple-negative (TN) (n = 24). Based on the morphology on DWI, the tumors were classified into two patterns: DWI-homogeneous or DWI-heterogeneous. If DWI-heterogeneous, an assessment of intratumoral SI on T2WI was performed: tumors with intratumoral high/low SI on T2WI were classified as Hete-H/Hete-L, respectively. The associations between (1) the morphological patterns on DWI and the five subtypes, and (2) the intratumoral SI patterns on T2WI and the five subtypes in DWI-heterogeneous were evaluated. RESULTS There was a significant association between (1) the morphological patterns on DWI and the five subtypes (p < 0.0001), and (2) the intratumoral SI patterns on T2WI and the five subtypes in DWI-heterogeneous (p < 0.0001). DWI-homogeneous was dominant in Luminal A-like (67.1%), and Hete-H was dominant in TN type (75%). Hete-H, suggesting the presence of intratumoral necrosis, included high proliferative and/or aggressive subtypes more frequently (80%) than Hete-L, suggesting the presence of fibrotic focus. Fibrotic focus was seen more commonly in the luminal subtypes. CONCLUSION The combined findings on DWI and T2WI revealed breast carcinomas that were associated with particular subtypes.
Collapse
Affiliation(s)
- Sachiko Yuen
- Breast Research Center, The Shinko Institution for Medical Research, Shinko Hospital, 1-4-47, Wakinohama Chuo, Kobe, 651-0072, Japan. .,Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan.
| | - Shuichi Monzawa
- Department of Diagnostic Radiology, Shinko Hospital, Kobe, Japan
| | - Seiji Yanai
- Breast Research Center, The Shinko Institution for Medical Research, Shinko Hospital, 1-4-47, Wakinohama Chuo, Kobe, 651-0072, Japan.,Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| | - Hajime Matsumoto
- Breast Research Center, The Shinko Institution for Medical Research, Shinko Hospital, 1-4-47, Wakinohama Chuo, Kobe, 651-0072, Japan.,Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| | - Yoshihiro Yata
- Breast Research Center, The Shinko Institution for Medical Research, Shinko Hospital, 1-4-47, Wakinohama Chuo, Kobe, 651-0072, Japan.,Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| | - You Ichinose
- Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| | - Teruyuki Deai
- Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| | - Takashi Hashimoto
- Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| | | | - Kazuhiko Yamagami
- Breast Research Center, The Shinko Institution for Medical Research, Shinko Hospital, 1-4-47, Wakinohama Chuo, Kobe, 651-0072, Japan.,Department of Breast Surgery and Oncology, Shinko Hospital, Kobe, Japan
| |
Collapse
|
15
|
Futamura M, Oba M, Masuda N, Bando H, Yamamoto Y, Kin T, Saeki T, Nagashima T, Kuwayama T, Toh U, Hirano A, Inokuchi M, Yamagami K, Mizuno Y, Kojima Y, Nakayama T, Yasojima H, Okada M, Ohno S. Abstract P2-16-13: Meta-analysis of nanoparticle albumin-bound paclitaxel (Nab-PTX) used as a neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01). Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p2-16-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Background] Nanoparticle albumin-bound paclitaxel (Nab-PTX) is a novel taxane formulation that was developed to avoid Cremophor/ethanol associated toxicities such as peripheral neuropathy and hypersensitive reactions. Since Taxol plays an important role in breast cancer therapy, Nab-PTX is considered safe and effective for metastatic breast cancer (MBC). According to these reports, a regimen including Nab-PTX in a neoadjuvant setting may induce preferable results. Several recent reports using a combination of Nab-PTX and anthracycline in neoadjuvant chemotherapy (NAC) have been published. In Japan, at least 34 small phase II studies using a Nab-PTX regimen have been registered with the University hospital Medical Information Network-Clinical Trial Registry (UMIN-CTR). We believe that integration of these data is important to evaluate the power of Nab-PTX, so we conducted a meta-analysis based on individual patient data (IPD). [Materials and Methods] This study is a collaborative meta-analysis of single arm trials using IPD to summarize the published and unpublished evidence of Nab-PTX-containing regimen efficacy. The main objective was to assess the rate of pathological complete response (pCR). Definitions of pCR were (1) ypT0 ypN0, (2) ypT0/is ypN0, and (3) ypT0/is ypNX. The secondary objectives were adverse events (AEs) (≥G3) and dose of administered Nab-PTX (mg/m2). First, we found 34 phase II studies registered from Feb 2011 to Jun 2016 using an electron search of UMIN-CTR. Second, we contacted each principal investigator (PI) to ask if they would participate in this study by providing individual data. Inclusion criteria were as follows: (1) Clinical trial(s) started after July 2010, (2) Principal investigator(s) in each trial agreed with study participation, (3) Nab-PTX-containing regimen was used for neoadjuvant chemotherapy in naive operable breast cancer patients, (4) Registered in UMIN with ethical review, (5) Clinical trials with more than 10 patients, (6) Completed clinical trials only were included (unpublished data are available), and (7) Each researcher was authorized by the research ethics committee to submit the data. pCR rates in all cases/each subtype were calculated with a 95% confidence interval (CI). The proportion of AEs and total Nab-PTX dose were also calculated. [Results] Among 34 studies, 16 studies (4 published, 12 unpublished) included 758 patients. Among these 16 studies, 5 (2 metastatic, 3 no treatment) were excluded for all analyses (n=753). After excluding 8 (3 declined surgery, 1 hospital transfer, 4 unknown), a total of 745 (including 2 PD, 1 death) were analyzed for the primary analysis. All HER2-positive cases were treated by combining Nab-PTX and trastuzumab. Crude overall percentages of pCR (ypT0ypN0, ypT0/isypN0, and ypT0/isypNX) were 18.1%, 26.0%, and 28.6%, respectively. In detail, 6.7%, 10.2%, and 13.4% for Luminal type (n=343), 26.3%, 31.5%, and 32.3% for triple negative (TNBC, n=232), 40.5%, 63.5%, and 68.9% for HER2-rich (n=74), 21.9%, 40.6%, and 42.7% for Luminal/HER2 type (n=96), respectively. AEs (≥G3) were observed as follows: 41.5% neutropenia, 32.3% leukopenia, 10.6% febrile neutropenia, 10.6% peripheral sensory neuropathy, 2.5% peripheral motor neuropathy, 6.4% myalgia, 5.5% arthralgia, 6.1% hepatobiliary disorders, 4.5% vomiting, 0.7%, cardiac disorders, and 0.9% infusion reaction. Only one patient died during FEC followed by Nab-PTX. [Conclusion] NAC regimen containing Nab-PTX was safe, and the efficacy was equal to or greater than regimens containing other taxanes. The combination Nab-PTX and trastuzumab is particularly useful and powerful against the HER2-positive subtype. However, the Nab-PTX-containing regimen is not as powerful against TNBC in a neoadjuvant setting.
Citation Format: Manabu Futamura, Mari Oba, Norikazu Masuda, Hiroko Bando, Yutaka Yamamoto, Takanori Kin, Toshiaki Saeki, Takeshi Nagashima, Takashi Kuwayama, Uhi Toh, Akira Hirano, Masafumi Inokuchi, Kazuhiko Yamagami, Yutaka Mizuno, Yasuyuki Kojima, Takahiro Nakayama, Hiroyuki Yasojima, Morihito Okada, Shinji Ohno. Meta-analysis of nanoparticle albumin-bound paclitaxel (Nab-PTX) used as a neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-16-13.
Collapse
Affiliation(s)
- Manabu Futamura
- 1Department of Surgical Oncology, Gifu University, Graduate School of Medicine, Gifu, Japan
| | - Mari Oba
- 2Department of Medical Statistics, Toho University, Tokyo, Japan
| | - Norikazu Masuda
- 3Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - Hiroko Bando
- 4Department of Breast-Thyroid-Endocrine Surgery, Tsukuba University, Tsukuba, Japan
| | - Yutaka Yamamoto
- 5Breast and Endocrine Surgery, Kumamoto University, Kumamoto, Japan
| | - Takanori Kin
- 6Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Toshiaki Saeki
- 7Department of Breast Oncology, Saitama Medical University International Medical Center, Saitama, Japan
| | - Takeshi Nagashima
- 8Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Japan
| | - Takashi Kuwayama
- 9Division of Breast Surgical Oncology, Showa University, Tokyo, Japan
| | - Uhi Toh
- 10Department of Surgery, Kurume University, Kurume, Japan
| | - Akira Hirano
- 11Department of Breast Surgery, Tokyo Women's Medical University, Medical Center East, Tokyo, Japan
| | - Masafumi Inokuchi
- 12Department of Breast and Endocrine Surgery, Kanazawa Medical University Hospital, Ishikawa, Japan
| | | | - Yutaka Mizuno
- 14Department of Breast Surgery, Yokkaichi Municipal Hospital, Yokkaichi, Japan
| | - Yasuyuki Kojima
- 15Division of Breast and Endocrine Surgery, St. Marianna University, Kawasaki, Japan
| | - Takahiro Nakayama
- 16Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan
| | - Hiroyuki Yasojima
- 17Dept. of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - Morihito Okada
- 18Research Institute for Radiation Biology and Medicine, Horoshima University, Horoshima, Japan
| | - Shinji Ohno
- 19Breast Oncology Center, Cancer Institute Hospital, Tokyo, Japan
| |
Collapse
|
16
|
Odan N, Kikawa Y, Matsumoto H, Minohata J, Suwa H, Hashimoto T, Okuno T, Miyashita M, Saito M, Yamagami K, Takao S. REAL-WORLD OUTCOMES OF PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH PALBOCICLIB: A MULTICENTER RETROSPECTIVE COHORT STUDY IN JAPAN. Breast 2019. [DOI: 10.1016/s0960-9776(19)30682-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
17
|
Miki M, Takao S, Konishi M, Shigeoka Y, Miyashita M, Suwa H, Imamura M, Okuno T, Hirokaga K, Miyoshi Y, Murase K, Yanai A, Yamagami K, Akazawa K. Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz418.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Tada H, Yamagami K, Nishikawa T, Nohara A, Kawashiri M, Takamura M. P6199Lipoprotein(a) and risk of chronic kidney disease among 4,235 Japanese hospitalized patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Lipoprotein (a) [Lp(a)] has been shown to be associated with the development of chronic kidney disease (CKD) among various ethnicities. In addition, recent Mendelian randomization studies have suggested that Lp(a) seems to be causally associated with CKD. However, few data exist regarding this issue among Japanese population.
Purpose
We aimed to investigate the association between serum Lp(a) and the CKD among Japanese population.
Methods
We retrospectively investigated 6,130 subjects whose serum Lp(a) had been measured for any reason (e.g. any operations which needs bed rest for a long duration, risk factors for atherosclerosis such as hypertension or diabetes) at our University Hospital from April 2004 to March 2014. We excluded 1,895 subjects due to the lack clinical data. We assessed their Lp(a), LDL cholesterol, HDL cholesterol, triglycerides, presence of hypertension, diabetes, chronic kidney disease, smoking, body mass index, presence of coronary artery disease (CAD), and presence of CKD (stage 3 or greater).
Results
When the study subjects were divided into 5 groups based on their CKD stage, there was a significant trend among their serum Lp(a) levels (P-trend = 2.7×10–13). Under these conditions, multiple regression analysis showed that Lp(a) was significantly associated with CKD [odds ratio (OR): 1.12, 95% confidence interval (CI): 1.08–1.17; p=1.3×10–7: per 10mg/dL)., independent of other classical risk factors, including age, gender, body mass index, hypertension, diabetes, smoking, LDL cholesterol and triglycerides. Under these conditions, Lp(a) was significantly associated with CAD [OR: 1.11, 95% CI: 1.06–1.16; p=1.7×10–6: per 10mg/dL), independent of the presence of CKD.
Conclusion
Serum Lp(a) was associated with the development of CKD independent of other classical risk factors among Japanese population as well.
Collapse
Affiliation(s)
- H Tada
- Kanazawa University, Kanazawa, Japan
| | | | | | - A Nohara
- Kanazawa University, Kanazawa, Japan
| | | | | |
Collapse
|
19
|
Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino H, Yamada K, Narui K, Kimura K, Akazawa K, Kohno N. Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment. Anticancer Res 2019; 39:4305-4314. [PMID: 31366522 DOI: 10.21873/anticanres.13596] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Revised: 06/30/2019] [Accepted: 07/02/2019] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Risk factors for chemotherapy-induced nausea and vomiting (CINV) with anthracycline-containing regimen for breast cancer patients remain unknown. The risk factors for CINV with FEC100 were investigated. PATIENTS AND METHODS Data on CINV events and patient backgrounds of 180 patients were collected from the first cycle of FEC100 treatment. In this regimen, patients were administered various antiemetics (ADs). The combinations of ADs were classified into four categories, while body mass index (BMI) was stratified into three categories. Risk factors were selected based on patient characteristics and combination of ADs. Risks for CINV were analyzed by univariate and multivariate analyses. RESULTS In the univariate analysis of nausea, BMI was a significant factor, while BMI and combination of ADs were significant in vomiting. In the multivariate analysis concerning nausea, BMI was a significant factor. In the analysis concerning vomiting, the combination of ADs and BMI were significant. CONCLUSION BMI was the most important risk factor for nausea and vomiting, while the combination of ADs was for vomiting.
Collapse
Affiliation(s)
| | - Kyoko Nakazawa
- Department of Medical Informatics, Niigata University, Niigata, Japan
| | - Yoshie Hasegawa
- Department of Breast Surgery, Hirosaki Municipal Hospital, Hirosaki, Japan
| | - Jun Horiguchi
- Department of Breast Surgery, International University of Health and Welfare, Chiba, Japan
| | | | - Takashi Ishikawa
- Department of Breast Oncology, Tokyo Medical University, Tokyo, Japan
| | - Shintaro Takao
- Department of Breast Surgery, Hyogo Cancer Center, Hyogo, Japan
| | - Seung Jim Kim
- Department of Breast and Endocrine Surgery, Osaka University, Osaka, Japan
| | | | | | - Muneharu Konishi
- Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan
| | - Yasushi Shigeoka
- Department of Medical Oncology, Yodogawa Christian Hospital, Osaka, Japan
| | - Masato Suzuki
- Department of Surgery, National Hospital Organization Chiba Medical Center, Chiba, Japan
| | - Tetsuya Taguchi
- Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Tomoyuki Kubota
- Department of Surgery, Kamiiida Daiichi General Hospital, Aichi, Japan
| | | | - Kimito Yamada
- Department of Breast Oncology, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan
| | - Kazutaka Narui
- Department of Breast and Endocrine Surgery, Yokohama City University Medical Center, Kanagawa, Japan
| | - Konomi Kimura
- Department of Medical Informatics, Niigata University, Niigata, Japan
| | - Kohei Akazawa
- Department of Medical Informatics, Niigata University, Niigata, Japan
| | - Norio Kohno
- Department of Breast Surgery, Kobe Kaisei Hospital, Hyogo, Japan
| | | |
Collapse
|
20
|
Tsuyuki S, Yamagami K, Yoshibayashi H, Sugie T, Mizuno Y, Tanaka S, Kato H, Okuno T, Ogura N, Yamashiro H, Takuwa H, Kikawa Y, Hashimoto T, Kato T, Takahara S, Katayama T, Yamauchi A, Inamoto T. Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy. Breast 2019; 47:22-27. [PMID: 31302389 DOI: 10.1016/j.breast.2019.06.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 06/11/2019] [Accepted: 06/29/2019] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND We have developed a surgical glove (SG)-compression therapy and reported that this method significantly reduced the overall occurrence of grade 2 or higher nanoparticle albumin-bound-paclitaxel (nab-PTX)-induced peripheral neuropathy (PN) from 76.1% to 21.4%. In this multicenter single-arm confirmatory study, we investigated the efficacy and safety of SG-compression therapy for the prevention of nab-PTX-induced PN, compared with the incidence of grade 2 or higher PN in published literature as controls. PATIENTS AND METHODS Primary breast cancer patients who received 260 mg/m2 of nab-PTX were eligible for this study. Patients wore two SGs (one size smaller than the tight-fitting size) in each hand for 90 min. PN was evaluated at each treatment cycle using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 and the Patient Neurotoxicity Questionnaire (PNQ). The temperature of each fingertip was measured using thermography. RESULTS Between October 2016 and June 2017, 58 patients were evaluated. The incidence of CTCAE grade 2 or higher PN was as low as 13.8% following SG-compression therapy. A goodness-of-fit test proved that the overall incidence of 13.8% grade 2 or higher PN in this study was comparable to the hypothesis-predicted value (13%). No adverse events, including compression intolerance or skin disorders caused by use of SG, were observed. SG-compression therapy significantly reduced the temperature of each fingertip by 1.3°C-2.3 °C compared to pre-chemotherapy level. CONCLUSIONS This study suggested the safety and efficacy of SG-compression therapy for the amelioration of CIPN. CLINICAL TRIAL NUMBER UMIN 000024836.
Collapse
Affiliation(s)
- Shigeru Tsuyuki
- Department of Breast Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka-city, Osaka, 543-8555, Japan.
| | - Kazuhiko Yamagami
- Department of Breast Surgery, Shinko Hospital, 1-4-47 Wakinohama-cho, Chuo-ku, Kobe-city, Hyogo, 651-0072, Japan. kazu.yama.-
| | - Hiroshi Yoshibayashi
- Department of Breast Surgery, Japanese Red Cross Society Wakayama Medical Center, 4-20, Komatsubara, Wakayama-city, Wakayama, 640-8558, Japan.
| | - Tomoharu Sugie
- Breast Surgery, Kansai Medical University Hospital, 2-3-1 Shin-machi, Hirakata-City, Osaka, 573-1191, Japan.
| | - Yutaka Mizuno
- Department of Breast Surgery, Yokkaichi Municipal Hospital, 2-Chome 2-37, Shibata, Yokkaichi-city, Mie, 510-8567, Japan.
| | - Satoru Tanaka
- Department of Breast Surgery, National Hospital Organization OsakaMinami Medical Center, 2-1 Kidohigashi-cho, Kawachinagano-City, Osaka, 586-8521, Japan.
| | - Hironori Kato
- Department of Breast Surgery, Kobe City Medical Center Central Hospital, 2-1-1, Minatojima Minamimachi, Chuo-ku, Kobe-city, Hyogo, 650-0047, Japan.
| | - Toshitaka Okuno
- Department of Breast Surgery, Kobe City Nishi-Kobe Medical Center, 5-7-1, Kojidai, Nishi-ku, Kobe, Hyogo, 651-2273, Japan.
| | - Nobuko Ogura
- Department of Breast Surgery, Kansai Electric Power Hospital, 2-1-7 Fukushima, Fukushima-ku, Osaka-city, Osaka, 553-0003, Japan.
| | - Hiroyasu Yamashiro
- Department of Breast Surgery, Tenri Hospital, 300 Mishima-cho, Tenri-city, Nara, 632-8552, Japan.
| | - Haruko Takuwa
- Department of Breast Surgery, Shiga General Hospital, 4-30 Moriyama 5-chome, Moriyama-city, Shiga, 524-8524, Japan.
| | - Yuichiro Kikawa
- Department of Breast Surgery, Kobe Minimally Invasive Cancer Center, 8-5-1, Minatojima Nakamachi, Chuo-ku, Kobe-city, Hyogo, 650-0046, Japan.
| | - Takashi Hashimoto
- Hashimoto Clinic, 1-7-2, Sumimoto Honnmati, Nada-ku, Kobe-city, Hyogo, 658-0051, Japan.
| | - Tatsushi Kato
- Department of Surgery, Yamato Takada Municipal Hospital, 1-1 Isonokita-cho, Yamatotakada-city, Nara, 635-8501, Japan.
| | - Sachiko Takahara
- Department of Breast Surgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20, Ohgimachi, Kita-ku, Osaka-city, Osaka, 530-8480, Japan.
| | - Toshiro Katayama
- Department of Medical Engineering, Faculty of Health Sciences, Morinomiya University of Medical Science, 1-26-16 Nankokita, Suminoe-ku, Osaka-city, Osaka, 559-8611, Japan.
| | - Akira Yamauchi
- Department of Breast Surgery, Nara Prefecture General Medical Center, 897-5 Shichijo-nishimachi 2-chome, Nara-city, Nara, 630-8581, Japan.
| | - Takashi Inamoto
- Department of Nursing Science, Tenri Health Care University, 80-1, Besho-cho, Tenri-city, Nara, 632-0018, Japan.
| |
Collapse
|
21
|
Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino Y, Yamada K, Kimura K, Akazawa K, Kohno N. Abstract P1-11-07: Risk analysis for chemotherapy induced nausea and vomiting (CINV) in patients receiving FEC100 treatment. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND:
Anthracycline-containing regimens are standard treatment options in adjuvant and neoadjuvant chemotherapy in breast cancer. Chemotherapy-induced nausea and vomiting (CINV) is experienced frequently in patients receiving these regimens, but the risk factors for CINV are unknown.
OBJECTIVE:
The aim of this study was to investigate risk factors for CINV in anthracycline-containing regimens retrospectively.
METHODS:
Data were collected from the JONIE study, which was conducted in order to estimate the efficacy of zoledronic acid in a neoadjuvant setting from March 2010 to June 2012 (UMIN000003261). A total of 180 patients were recruited, and we used CINV data from the first cycle of FEC100 treatment and patient backgrounds. As the protocol regulation allowed the use of antiemetic drugs,in the first cycle of the FEC100 regimen, patients received various types of antiemetic agents, which we classified into four groups: Dexamethasone (DEX)+5-HT3 receptor antagonist (5-HT3)+neurokinin-1 receptor antagonist (NK1) (DEX+5-HT3+NK1) group; Dexamethasone (DEX)+5-HT3 receptor antagonist (5-HT3) (DEX+5HT3) group; Dexamethasone (DEX)+5-HT3 receptor antagonist (5-HT3)+dopamine receptor antagonist (DRA) (DEX+5HT3+DRA) group; and Dexamethasone (DEX)+5-HT3 receptor antagonist (5-HT3)+neurokinin-1 receptor antagonist (NK1)+ dopamine receptor antagonist (DRA) (DEX+5-HT3+NK1+DRA) group. Risk factors were selected from patient backgrounds and the combinations of antiemetic drugs. In patient backgrounds, the body mass index (BMI) was stratified into 3 categories: Less than 18.5 (underweight group); equal to or more than 18.5 but less than 25 (standard BMI group); and equal to or more than 25 (overweight group). The risks for CINV were analyzed by univariate and multivariate analyses. P values of less than 0.05 were defined as significant.
RESULTS:
In a univariate analysis of nausea, the body mass index (BMI) was the only significant factor (P<0.05). On the other hand, BMI and the combination of antiemetic drugs were significant factors in vomiting. (P<0.05 and 0.005, respectively). In a multivariate analysis of nausea, the P value for BMI was 0.02. The odds ratio for the underweight group was 7.745 (confidence interval: 2.171 to 27.634) compared with the standard BMI group. In a multivariate analysis of vomiting, BMI and the combination of antiemetic drugs were significant risk factors (P=0.025 and 0.023, respectively). The odds ratio for the underweight group was 3.481 (confidence interval: 1.183 to 10.241)compared with the standard BMI group. Furthermore, the odds ratios in the DEX+5-HT3+DRA and DEX+5HT3 groups were 5.005 (confidence interval: 1.543 to 16.239) and 4.178 (confidence interval: 1.428 to 12.222), respectively, compared with the DEX+5-HT3+NK1 group, which was consistent with the CINV guidelines in 2011.
CONCLUSIONS:
This study revealed that BMI was the most important risk factor for nausea, and that BMI and the combination of antiemetic drugs were risk factors for vomiting. Underweight-patients tend to have CINV in anthracycline-containing regimen. The DEX+5-HT3+NK1 group was the best antiemetic drug combination. These result show that following the CINV guideline treatment is mandatory in order to prevent CINV.
Citation Format: Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino Y, Yamada K, Kimura K, Akazawa K, Kohno N. Risk analysis for chemotherapy induced nausea and vomiting (CINV) in patients receiving FEC100 treatment [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-07.
Collapse
Affiliation(s)
- M Hayashi
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Nakazawa
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - Y Hasegawa
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - J Horiguchi
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - D Miura
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - T Ishikawa
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - S Takao
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - SJ Kim
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Yamagami
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - M Miyashita
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - M Konishi
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - Y Shigeoka
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - M Suzuki
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - T Taguchi
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - T Kubota
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - Y Tanino
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Yamada
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Kimura
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Akazawa
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - N Kohno
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| |
Collapse
|
22
|
Maeshima Y, Takahara S, Yamauchi A, Yamagami K, Sugie T, Yamashiro H, Kato H, Torii M, Takada M, Torii M. Abstract P3-03-21: Usefulness of sentinel lymph node biopsy by indocyanine green fluorescence method for cN0 breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-03-21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Indocyanine green (ICG) fluorescence method (ICG-f) has been recently widely used in sentinel lymph node (SLN) detection. The advantages of ICG-f are no radiation exposure, no limitation to use in high-volume medical centers without radioactive facility, and to confirm lymph flow as a real-time image from outside the body. ICG-f identified an average of 2.3-3.4 SLNs and the detection rate was 99%, compared to 1.7-2 SLNs by RI methods. Long-term observation after SNB using ICG-f has not been reported, including arm lymphedema as the complication of this method.We evaluate the usefulness of SLN biopsy (SNB) for cN0 breast cancer patients from data of multicenter cohort study on long-term results after negative SNB by ICG-f.
Methods. Eleven hundred and thirty-two women were enrolled who had histologically proved clinical stage T1-4, pN0, M0 primary invasive breast cancer with SNB using ICG-f (ICG alone or combination of RI/blue dye method) sparing axillary lymph node dissection from May 2007 to December 2015. This study is retrospective, multicenter cohort study conducted at 6 centers in Japan. Primary endpoint is axillary recurrence rate. We analyzed the correlation with the axillary recurrence and adjuvant systemic therapy, adjuvant radiotherapy, and the clinicopathological characteristics. Secondary endpoint is lymphedema.
Results and Discussion. The median follow-up time was 41 (range 21-117) months, and axillary recurrence was found in 6 patients (0.53%). Five out of 6 patients were not received standard adjuvant systemic therapy or adjuvant radiation therapy after breast conserving surgerybecause of patient's preference or old age. Lymphedema was identified only 4 patients in 632 patients. It is reported that axillary recurrence after SNB was 0.3-1.65%, which was consistent with our result. Lymphedema was not frequent in patients received SNB using ICG-f, because SLNs are removed along with lymphatic ducts in the limited area of axillary adipose tissue.
Conclusion.Axillary recurrence after negative SNB using ICG-f was comparable to RI or blue dye method. It might be important to perform appropriate adjuvant medication or radiation therapy for preventing axillary recurrence after SNB using ICG-f.
Next, ICG-f after neoadjuvant chemotherapy is to be investigated, because itis reported that removing more than 2 SLNs were associated with a lower likelihood of false negative ratio in patients with clinically node-positive disease converted to clinically node-negative after chemotherapy, and ICG-f might overcome this issue.
Citation Format: Maeshima Y, Takahara S, Yamauchi A, Yamagami K, Sugie T, Yamashiro H, Kato H, Torii M, Takada M, Torii M. Usefulness of sentinel lymph node biopsy by indocyanine green fluorescence method for cN0 breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-21.
Collapse
Affiliation(s)
- Y Maeshima
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - S Takahara
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - A Yamauchi
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - K Yamagami
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - T Sugie
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - H Yamashiro
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - H Kato
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - M Torii
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - M Takada
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| | - M Torii
- Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan; Shinko Hospital, Kobe, Japan; Kansai Medical University Hospital, Osaka, Japan; Tenri Hospital, Nara, Japan; Kobe City Medical Center General Hospital, Kobe, Japan; Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|
23
|
Nakatsukasa K, Kikawa Y, Kotake T, Yamagami K, Tsuyuki S, Yamashiro H, Suwa H, Sugie T, Okuno T, Kato H, Takahara S, Nakayama I, Ogura N, Moriguchi Y, Takata M, Suzuki E, Yoshibayashi H, Ishiguro H, Taguchi T, Toi M. Prospective cohort study of real world chemotherapy sequence for metastatic breast cancer (KBCRN A001: E-SPEC study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Yamagami K, Matsumoto H, Hashimoto T, Yanai S, Yuen S, Yata Y, Ichinose Y, Deai T, Toi M. The application of indocyanine green fluorescence navigation method to a sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy270.255] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Tsuyuki S, Yamagami K, Yoshibayashi H, Sugie T, Mizuno Y, Tanaka S, Kato H, Okuno T, Ogura N, Yamashiro H, Takuwa H, Kikawa Y, Hashimoto T, Kato T, Takahara S, Yamauchi A, Inamoto T. Effectiveness of surgical glove compression therapy as a prophylactic method against nab-paclitaxel induced peripheral neuropathy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy300.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, Suwa H, Ohtani S, Ito T, Yasuno S, Morita S, Ohno S, Toi M. Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study. Breast Cancer (Auckl) 2018; 12:1178223418786243. [PMID: 30013356 PMCID: PMC6043925 DOI: 10.1177/1178223418786243] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/17/2018] [Accepted: 06/06/2018] [Indexed: 01/03/2023]
Abstract
Background: There are little data on the usefulness of trastuzumab (TZM) retreatment as the first-line treatment for patients with HER2 (human epidermal growth factor receptor 2)–positive breast cancer recurrence after perioperative treatment with TZM. Aim: To clarify the outcome and safety of TZM retreatment in patients with recurrent HER2-positive breast cancer. Method: An observational study was conducted on patients who relapsed after primary systemic therapy with TZM using the central registration system. The primary end point was progression-free survival (PFS). Secondary end points consisted of the response rate, overall survival (OS), and safety. Result: In total, 34 patients were registered between July 2009 and June 2012. The median follow-up time was 23.7 months (2-24 months). The 1- and 2-year PFS rates were 46.9% (95% confidence interval (95% CI): 29.2%-62.9%) and 29.8% (95% CI: 15.0%-46.3%), respectively (median 10.6 months). The median PFS time for patients receiving TZM combined with CTx was 13.9 months. The 1-and 2-year OR rates were 93.9 (95% CI: 77.9%-98.4%) and 84.8% (95% CI: 67.4%-93.4%). Trastuzumab-induced grade 3/4 adverse events were not observed. Conclusions: This study suggests that the PFS and OS in Japanese patients who relapsed after perioperative TZM therapy improved or were similar to those in previous reports. Differences in patient backgrounds and treatments must be considered when interpreting the results. Trastuzumab should be used combination with CTx and/or HTx for retreatment. Retreatment with TZM is safe. Trial registration: UMIN000002738.
Collapse
Affiliation(s)
| | - Masataka Sawaki
- Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Norikazu Masuda
- Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
| | - Yasuhiro Okumura
- Department of Breast Oncology, Kumamoto Shinto General Hospital, Kumamoto, Japan
| | - Toshimi Takano
- Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan
| | - Eriko Tokunaga
- Department of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
| | - Tsuyoshi Saito
- Department of Breast Surgery, Japnese Red Cross Saitama Hospital, Saitama, Japan
| | - Yasuaki Sagara
- Department of Breast Surgery, Social Medical Corporation Hakuaikai, Sagara Hospital, Kagoshima, Japan
| | - Kosuke Yamazaki
- Department of Surgery, Japanese Red Cross Hokkaido College of Nursing, Kitami, Japan
| | - Yoshihiro Kawaguchi
- Department of Breast Surgery, Murakami Memorial Hospital, Asahi University, Gifu, Japan
| | - Tecchuu Lee
- Department of Breast Surgery, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan
| | - Shinji Ozaki
- Department of Breast Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan
| | | | | | - Katsumasa Kuroi
- Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
| | - Hirofumi Suwa
- Department of Breast Surgery, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | - Shoichiro Ohtani
- Division of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan
| | - Toshikazu Ito
- Department of Surgery, Rinku General Medical Center, Osaka, Japan
| | - Shinji Yasuno
- Department of EBM Research, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
| | - Satoshi Morita
- Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Shinji Ohno
- Breast Oncology Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - Masakazu Toi
- Department of Surgery (Breast Surgery), Graduate School of Medicine Kyoto University, Kyoto, Japan
| |
Collapse
|
27
|
Yamagami K, Matsumoto H, Hashimoto T, Yanai S, Yuen S, Kuramitu H, Ichinose Y, Deai T, Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence navigation method after neoadjuvant chemotherapy for patients with clinically node-positive breast cancer. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e12108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12108 Background: Sentinel lymph node biopsy (SNB) for initially clinically node-positive (cN1) after neoadjuvant chemotherapy (NAC) is controversial. Even if approximately 40% of node positive disease converts to node negative after NAC, SNB using blue dye (BD) and/or radioisotope (RI) agent showed the high false-negative rate (FNR) (SENTINA, ACOSOG Z1071). These trials showed the accuracy of SNB was closely related to the number of sentinel lymph nodes (SNs) removed. We presented the efficacy of indocyanine green (ICG) fluorescence navigation method for SNB in clinically node-negative (cN0) patients (ASCO2008). The ICG method can provide higher numbers of SNs and it helps to identify lymph nodes with the remained metastases. Methods: Of 1900 patients (Jan. 2010 - Dec. 2016), 242 women with cN0 or cN1 received NAC: Group 0 (cN0 before NAC, n=150), Group 1 (cN1 converted ycN0 after NAC, n=71) , Group 2 (cN1 remained ycN1 after NAC, n=21). Node status was evaluated by ultrasound. All patients underwent SNB using both ICG- and BD-method together. Fluorescence images were obtained by a CCD camera with a cut filter as a detector, light emitting diodes at 760nm as the light source. ALND was performed in Group1 and Group 2. Results: Pathological complete nodal response rate (pcNRR) was 48.4%. Table shows the number of SNs removed by ICG or BD. SNs detection rates (ICG, BD): Group 0 (98.7%, 84.7%), Group 1 (98.6%, 83.1%), Group 2 (85.7%, 47.6%). Resulting of a FNR (ICG, BD): Group 1 (5.7%, 15.3%), Group 2 (22.2%, 60.0%). Conclusions: The pcNRR and a FNR of BD in Group 1 were similar to those of SENTINA or ACOSOGZ 1071 trials. In patients who converted from cN1 to ycN0, the fluorescent ICG method showed a high detection rate of SNs and a low FNR. [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Masakazu Toi
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
28
|
Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Kohno N. Abstract P5-16-10: Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND and AIM:
Findings from a randomized phase 2 JONIE1 trial in women with HER2-negative early breast cancer have shown that the addition of zoledronic acid (ZOL) to neoadjuvant chemotherapy (CT) has potential anticancer benefits in postmenopausal and triple-negative breast cancer patients. We report the data for the prespecified secondary endpoint of disease-free survival (DFS).
METHODS:
We enrolled women with HER2-negative early breast cancer and randomly assigned them to receive CT or CT+ZOL (CTZ). All patients received 4 cycles of FEC100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2), followed by 12 cycles of paclitaxel at 80 mg/m2 weekly. ZOL (4 mg) was administered 3-4 times weekly for 7 weeks to the CTZ group patients. Definitive surgery was performed 3-4 weeks after the last paclitaxel dose. The primary endpoint was pathological complete response (pCR). The secondary endpoints were the clinical response rates, rate of breast-conserving surgery, safety, and DFS (defined as the time from randomization to disease occurrence or death). The trial is registered as UMIN000003261 (www.umin.ac.jp/english/) with ongoing follow-up.
FINDINGS:
Of the 188 patients enrolled, 95 were assigned to the CT group and 93 to the CTZ group. The mean (95% CI) DFS time of the CT group was 5.15 years (4.83-5.47) and that of the CTZ group was 5.38 years (5.11-5.66). The 3-year DFS rate was 84.6% (95% CI 77.2-92.0) in the CT group and 90.7% (84.6-96.8) in the CTZ group with no significant difference (p = 0.120). The particular benefit from ZOL for the neoadjuvant CT seen as improvement of the pCR rate was indicated in the 3-year DFS period for triple-negative cancer cases (CT vs CTZ: 70.6% vs 94.1%), but not for postmenopausal cases.
CONCLUSIONS:
ZOL slightly improved DFS when combined with CT. Although a significant difference was not found in this study, plans are underway for conducting a combined analysis of 3 neoadjuvant CT trials together with ZOL. The improvement of the pCR rate may be associated with DFS in triple-negative cases. Previous studies have shown that ZOL was more efficacious in an estrogen-suppressed condition. However, the short-term application of ZOL in this study may not be sufficient to improve the outcome in postmenopausal patients.
Citation Format: Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Kohno N. Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-10.
Collapse
Affiliation(s)
- T Ishikawa
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - K Akazawa
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - Y Hasegawa
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - H Tanino
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - J Horiguchi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - D Miura
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Hayashi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - S Takao
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - SJ Kim
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - K Yamagami
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Miyashita
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Konishi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - Y Shigeoka
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Suzuki
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - T Taguchi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - T Kubota
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - N Kohno
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| |
Collapse
|
29
|
Kaise H, Ishikawa T, Miura D, Hasegawa Y, Horiguchi J, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka Y, Yamagami K, Suzuki M, Taguchi T, Akazawa K, Kohno N. Abstract P3-07-50: Early and accurate prediction of pathological response by magnetic resonance imaging and ultrasonography in patients undergoing neoadjuvant chemotherapy for operable breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy (NAC) reduces tumor size, and increases the frequency of breast-conserving surgery in operable breast cancers. Response predictions to NAC are made based on diagnostic imaging.
Although various studies have reported the optimal timing for diagnostic imaging, this still remains unclear.
Purpose: To identify the optimal timing of diagnostic imaging for the response prediction to NAC, and to evaluate the accuracy of response prediction.
Methods: We evaluated 146 cases enrolled in the JONIE-1 study (a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a NAC in patients with HER2-negative primary breast cancer). The chemotherapy regimen was FEC100×4 courses followed by weekly paclitaxel 80×12 courses (± zoledronic acid). Statistical analysis of the association between the tumor reduction ratio and the histopathological response and the prediction of pathological complete response (pCR) was performed using JMP software. The maximum tumor diameter was evaluated using magnetic resonance imaging and ultrasound on each patient 3 times (before NAC, after FEC treatment, after NAC) and tumor reduction ratios were calculated.
Results: The average age of the patients was 49.8 years old. The menopause status was pre-menopause in 84 patients, and post-menopause in 58 patients. Regarding the subtype classification, 116 patients were of the luminal type (Lum) and 26 patients were triple negative (TN), and the Ki-67 labeling index had a median of 25% (1%-93%).
Pathological examination demonstrated that 16 patients had pCR(11.3%, Lum, 9;TN: 7), and 126 patients had non-pCR (88.7%, Lum:107; TN:19). Seven patients had clinical-CR (4.8%, Lum: 4; TN: 3) at post-FEC, and 26 patients (17.8%, Lum: 20; TN: 6) at post-NAC. The prediction of pCR at post-FEC and post-NAC was evaluated by single variable analysis, resulting in an AUC (0.75645) p=0.0017 at post-FEC, and AUC (0.76563) p=0.0001 at post-NAC. The sensitivity / specificity / positive predictive value / negative predictive value were 0.625 / 0.873 / 0.385 / 0.948 at post-FEC, 0.250 / 0.976 / 0.571 / 0.911 at post-NAC, respectively. In TN cases, the values were 0.714 / 0.947 / 0.833 / 0.900 in post-FEC, and 0.429 / 1.000 / 1.000 / 0.826 in post-NAC.
Conclusions: Diagnostic imaging evaluation performed after FEC treatment was useful for the prediction of pCR. Furthermore, the reliability was high in Triple Negative Sub type, but is affected by the existence of residual tumors in Luminal type.
Citation Format: Kaise H, Ishikawa T, Miura D, Hasegawa Y, Horiguchi J, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka Y, Yamagami K, Suzuki M, Taguchi T, Akazawa K, Kohno N. Early and accurate prediction of pathological response by magnetic resonance imaging and ultrasonography in patients undergoing neoadjuvant chemotherapy for operable breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-50.
Collapse
Affiliation(s)
- H Kaise
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - T Ishikawa
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - D Miura
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - Y Hasegawa
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - J Horiguchi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Hayashi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - S Takao
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - SJ Kim
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - H Tanino
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Miyashita
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Konishi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - Y Shigeoka
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - K Yamagami
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Suzuki
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - T Taguchi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - K Akazawa
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - N Kohno
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| |
Collapse
|
30
|
Kusama T, Yamagami K, Hasegawa M, Sone N, Kokado Y, Koshiba T, Ichikawa K. [An Elderly Patient with Local Recurrence of Gastric Cancer Responding Completely to S-1 Monotherapy]. Gan To Kagaku Ryoho 2016; 43:247-250. [PMID: 27067692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
An 80-year-old man with a local recurrence of gastric cancer was treated with S-1 monotherapy leading to a complete response(CR).The patient was diagnosed with gastric cancer and underwent a distal gastrectomy with lymph node dissection. Pathological findings showed tub2>por1, pT3 (SS), pN2, pStage III A.Five months after surgery, the patient presented with redness of the abdominal skin.Computed tomography (CT) revealed massive tumors in the abdominal cavity with invasion to the abdominal wall. He was administered S-1, 80 mg/body/day for 14 days, followed by a 7-day rest.After 2 courses of treatment, CT showed a dramatic reduction of the tumors. After 6 months, the tumor tissue completely disappeared and he had a CR.Administration of S-1 was continued for 2 years and 6 months.There was no relapse for 3 years after discontinuation.S -1 monotherapy appears to be a feasible and effective therapy for elderly patients with recurrent gastric cancer.
Collapse
|
31
|
Hasegawa Y, Tanino H, Horiguchi J, Miura D, Ishikawa T, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Akazawa K, Kohno N. Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study). PLoS One 2015; 10:e0143643. [PMID: 26633806 PMCID: PMC4669153 DOI: 10.1371/journal.pone.0143643] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 11/05/2015] [Indexed: 11/18/2022] Open
Abstract
Purpose Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption by inhibiting the mevalonate pathway. Its benefit for the prevention of skeletal complications due to bone metastases has been established. However, the antitumor efficacy of ZOL, although suggested by multiple preclinical and clinical studies, has not yet been clinically proven. We performed the present randomized Phase 2 trial to investigate the antitumor effect of ZOL with chemotherapy (CT). Methods Asian patients with HER2-negative invasive breast cancer were randomly assigned to either the CT or CT+ZOL (CTZ) group. One hundred and eighty-eight patients were randomized to either the CT group (n = 95) or the CTZ group (n = 93) from March 2010 to April 2012, and 180 patients were assessed. All patients received four cycles of FEC100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2), followed by 12 cycles of paclitaxel at 80 mg/m2 weekly. ZOL (4 mg) was administered three to four times weekly for 7 weeks to the patients in the CTZ group. The primary endpoint was the pathological complete response (pCR) rate, which was defined as no invasive cancer in the breast tissue specimen. Safety was assessed in all patients who received at least one dose of the study drug. Results This randomized controlled trial indicated that the rates of pCR in CTZ group (14.8%) was doubled to CT group (7.7%), respectively (one-sided chi-square test, p = 0.068), though the additional efficacy of zoledronic acid was not demonstrated statistically. The pCR rate in postmenopausal patients was 18.4% and 5.1% in the CTZ and CT groups, respectively (one-sided Fisher’s exact test, p = 0.071), and that in patients with triple-negative breast cancer was 35.3% and 11.8% in the CTZ and CT groups, respectively (one-sided Fisher’s exact test, p = 0.112). Thus the addition of ZOL to neoadjuvant CT has potential anticancer benefits in postmenopausal patients and patients with triple-negative breast cancer. Further investigation is warranted. Trial Registration University Hospital Medical Information Network. UMIN000003261.
Collapse
Affiliation(s)
- Yoshie Hasegawa
- Department of Breast Surgery, Hirosaki Municipal Hospital, Aomori, Japan
- * E-mail:
| | - Hirokazu Tanino
- Department of Breast and Thyroid Surgery, Kitasato University Hospital, Kanagawa, Japan
| | - Jun Horiguchi
- Department of Breast and Endocrine Surgery, Gunma University Hospital, Gunma, Japan
| | - Daishu Miura
- Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan
| | - Takashi Ishikawa
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Kanagawa, Japan
| | - Mitsuhiro Hayashi
- Department of Breast Oncology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
| | - Shintaro Takao
- Department of Breast Surgery, Hyogo Cancer Center, Hyogo, Japan
| | - Seung Jin Kim
- Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan
| | | | | | - Muneharu Konishi
- Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan
| | - Yasushi Shigeoka
- Department of Medical Oncology, Yodogawa Christian Hospital, Osaka, Japan
| | - Masato Suzuki
- Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan
| | - Tetsuya Taguchi
- Department of Endocrine & Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Tomoyuki Kubota
- Department of Breast Surgery, Kamiiida Daiichi General Hospital, Nagoya, Japan
| | - Kouhei Akazawa
- Department of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata
| | - Norio Kohno
- Department of Breast Oncology, Kobe Kaisei Hospital, Hyogo, Japan
| | | |
Collapse
|
32
|
Egawa C, Hirokaga K, Takao S, Yamagami K, Miyashita M, Baba M, Ichii S, Konishi M, Kikawa Y, Minohata J, Okuno T, Miyauchi K, Wakita K, Suwa H, Hashimoto T, Nishino M, Matsumoto T, Hidaka T, Konishi Y, Sakoda Y, Miya A, Mitsunobu M, Nishikawa H, Kono S, Kokufu I, Sakita I, Kitatsuji K, Oh K, Miyoshi Y. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. Int J Clin Oncol 2015; 21:262-269. [PMID: 26411314 DOI: 10.1007/s10147-015-0905-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2015] [Accepted: 09/08/2015] [Indexed: 11/29/2022]
Abstract
BACKGROUND Endocrine treatment-related adverse events have a strong impact on patients' quality of life and sometimes result in treatment discontinuation. Since joint symptoms are the most frequently recognized side effect of aromatase inhibitors, evaluation of associated risk factors may yield significant findings. PATIENTS AND METHODS A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455). Patients completed the self-report questionnaire at baseline and after 3, 6, 9, and 12 months of treatment for evaluation of frequency of treatment-related joint symptoms (arthralgia, decrease in range of joint motion, and joint stiffness). RESULTS We obtained PROs from 362 patients (92.6 %) at baseline and at one or more subsequent points. New or worsening from baseline of joint symptoms were reported by 260 patients (71.8 %). More than 90 % of the symptoms were mild or moderate and nearly 80 % had occurred by 6 months. Multivariate analysis showed that a short time span after menopause [odds ratio (OR) 0.95, 95 % confidence interval (CI) 0.90-0.99; P = 0.02] and adjuvant chemotherapy (OR 2.29, 95 % CI 1.06-4.95; P = 0.03) were significant independent risk factors for joint symptoms. No significant relationships between body mass index (BMI) and joint symptoms were identified. Eighteen patients discontinued treatment during the 1st year and eight of them reported joint symptoms. CONCLUSION Taking into consideration that PROs may yield higher prevalence rates than physician ratings for symptoms published in pivotal clinical trials, we found that a short time span after menopause and use of adjuvant chemotherapy, but not high BMI, were significantly associated with joint symptoms. These findings might prove useful for counseling before initiating treatment with adjuvant aromatase inhibitors in postmenopausal Japanese women.
Collapse
Affiliation(s)
- Chiyomi Egawa
- Department of Surgery, Kansai Rosai Hospital, Inaba-so, 3-1-69, Amagasaki, Hyogo, 660-8511, Japan
| | - Kouichi Hirokaga
- Department of Breast Surgery, Hyogo Cancer Center, Kitaoji-cho, 13-70, Akashi, Hyogo, 673-8558, Japan
| | - Shintaro Takao
- Department of Breast Surgery, Hyogo Cancer Center, Kitaoji-cho, 13-70, Akashi, Hyogo, 673-8558, Japan
| | - Kazuhiko Yamagami
- Department of Breast Surgery, Shinko Hospital, Wakinohama-cho, 1-4-47, Chuo-ku, Kobe, Hyogo, 651-0072, Japan
| | - Masaru Miyashita
- Department of Surgery, Kohnan Hospital, Kamokogahara, 1-5-16, Higashinada-ku, Kobe, Hyogo, 658-0064, Japan
| | - Masashi Baba
- Department of Surgery, Itami City Hospital, Koyaike, 1-100, Itami, Hyogo, 664-8540, Japan
| | - Shigetoshi Ichii
- Rokko Island Hospital, Koyochonaka, 2-11, Higashinada-ku, Kobe, Hyogo, 658-0032, Japan
| | - Muneharu Konishi
- Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Rokutanji-cho, 13-9, Nishinomiya, Hyogo, 662-0918, Japan
| | - Yuichiro Kikawa
- Department of Surgery, Kobe City Medical Center West Hospital, Ichiban-cho, 2-4, Nagata-ku, Kobe, Hyogo, 653-0013, Japan
| | - Junya Minohata
- Department of Surgery, Kobe Kyodo Hospital, Kubo-cho, 2-4-7, Nagata-ku, Kobe, Hyogo, 653-0041, Japan
| | - Toshitaka Okuno
- Nishi-kobe Medical Center, Kojidai, 5-7-1, Nishi-ku, Kobe, Hyogo, 651-2273, Japan
| | - Keisuke Miyauchi
- Miyauchi Clinic, Mukonoso, 4-10-5, Amagasaki, Hyogo, 661-0035, Japan
| | - Kazuyuki Wakita
- Chayamachi Breast Clinic, Chayamachi, 3-1, Kita-ku, Osaka, Osaka, 530-0013, Japan
| | - Hirofumi Suwa
- Hyogo Prefectural Tsukaguchi Hospital, Minamitsukaguchi-cho, 6-8-17, Amagasaki, Hyogo, 661-0012, Japan
| | - Takashi Hashimoto
- Hashimoto Clinic, Sumiyoshihommachi, 1-7-2, Higashinada-ku, Kobe, Hyogo, 658-0051, Japan
| | - Masayuki Nishino
- Department of Surgery, Takarazuka Municipal Hospital, Kohama, 4-5-1, Takarazuka, Hyogo, 665-0827, Japan
| | - Takashi Matsumoto
- Department of Surgery, Kinki Central Hospital, Kurumazuka, 3-1, Itami, Hyogo, 664-8533, Japan
| | - Toshiharu Hidaka
- Kobe Century Memorial Hospital, Misaki-cho, 1-9-1, Hyogo-ku, Kobe, Hyogo, 652-0855, Japan
| | - Yutaka Konishi
- Kobe Urban Breast Clinic, Kumoidori, 4-1-6, Chuo-ku, Kobe, Hyogo, 651-0096, Japan
| | - Yoko Sakoda
- Department of Breast Surgery, Hyogo Prefectural Kakogawa Medical Center, Kanno-cho Kanno, 203, Kakogawa, Hyogo, 675-8555, Japan
| | - Akihiro Miya
- Department of Surgery, Kuma Hospital, Shimoyamatedori, 8-2-35, Chuo-ku, Kobe, Hyogo, 650-0011, Japan
| | - Masao Mitsunobu
- Department of Breast and Endocrine Surgery, Meiwa Hospital, Agenaruo-cho, 4-31, Nishinomiya, Hyogo, 663-8186, Japan
| | - Hidefumi Nishikawa
- Nishikawa Clinic, Nishidaimotsu-cho, 12-41, Amagasaki, Hyogo, 660-0827, Japan
| | - Seishi Kono
- Department of Breast and Endocrine Surgery, Kobe University School of Medicine, Kusunoki-cho, 7-5-2, Chuo-ku, Kobe, Hyogo, 650-0017, Japan
| | - Ikuo Kokufu
- Kokufu Breast Clinic, Nakayamadera, 1-10-6, Takarazuka, Hyogo, 665-0861, Japan
| | - Isao Sakita
- Sakita Clinic, Wajo-cho, 2-35-101, Nishinomiya, Hyogo, 662-0971, Japan
| | - Koushiro Kitatsuji
- Kitatsuji Clinic, Nishitachibana-cho, 3-1-1, Amagasaki, Hyogo, 660-0054, Japan
| | - Koushi Oh
- Kobe Adventist Hospital, Arinodai, 8-4-1, Kita-ku, Kobe, Hyogo, 651-1321, Japan
| | - Yasuo Miyoshi
- Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo College of Medicine, Mukogawa-cho, 1-1, Nishinomiya, Hyogo, 663-8501, Japan.
| |
Collapse
|
33
|
Tane K, Egawa C, Takao S, Miyashita M, Yamagami K, Baba M, Ichii S, Konishi M, Kikawa Y, Minohata J, Okuno T, Miyauchi K, Miyoshi Y. Effect of body mass index and menopausal disorders during menopause on vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: A prospective multicenter cohort study of patient-reported outcomes. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.9619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | - Yuichiro Kikawa
- Kobe City Hospital Organization Kobe City Medical Centar West Hospital, Kobe, Japan
| | | | | | | | - Yasuo Miyoshi
- Department of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| |
Collapse
|
34
|
Yamazaki S, Morio H, Inami M, Ito M, Fujii Y, Hanaoka K, Yamagami K, Okuma K, Morita Y, Shirakami S, Inoue T, Miyata S, Higashi Y, Seki N. THU0101 ASP015K: A Novel Jak Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
Uchitomi N, Oomae H, Toyota H, Yamagami K, Kambayashi T. Magnetic, electrical and structural properties of annealed ferromagnetic (Zn,Sn)As 2:Mn thin films on InP substrates: comparison with undoped ZnSnAs 2. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20147503007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Fukami H, Hatano Y, Kishi M, Katagiri K, Fujiwara S, Yamagami K. Ingestion of sphingolipids restores the skin permeability barrier after damage caused by repeated ultraviolet B irradiation in mice. Clin Exp Dermatol 2013; 39:71-2. [DOI: 10.1111/ced.12162] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/05/2013] [Indexed: 11/30/2022]
Affiliation(s)
- H. Fukami
- Central Research Institute, Mizkan Group Corporation; Handa Aichi 475-8585 Japan
| | - Y. Hatano
- Research Team for Functional Genomics, Department of Dermatology, Faculty of Medicine; Oita University; Oita Japan
| | - M. Kishi
- Central Research Institute, Mizkan Group Corporation; Handa Aichi 475-8585 Japan
| | - K. Katagiri
- Research Team for Functional Genomics, Department of Dermatology, Faculty of Medicine; Oita University; Oita Japan
- Department of Dermatology; Koshigaya Hospital, Dokkyo Medical University; Saitama Japan
| | - S. Fujiwara
- Research Team for Functional Genomics, Department of Dermatology, Faculty of Medicine; Oita University; Oita Japan
| | - K. Yamagami
- Central Research Institute, Mizkan Group Corporation; Handa Aichi 475-8585 Japan
| |
Collapse
|
37
|
Horiguchi J, Hasegawa Y, Miura D, Ishikawa T, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka Y, Yamagami K, Akazawa K, Kohno N. A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.1029] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1029 Background: Zoledronic acid (ZOL) has been found to have a synergistic anti-proliferative effect when used in combination with antitumor drugs. We investigated the synergistic effect of ZOL, assessed by pathological complete response (pCR) rate, when added to neoadjuvant chemotherapy (CT) in the primary tumor. Methods: Women with resectable invasive Stage IIA-IIIB breast cancer who are HER2-negative, between 20 and 70 years of age, and ECOG PS 0-1 were eligible. CT regimen was FEC100 q3w × 4 cycles followed by weekly paclitaxel for 12 cycles. ZOL 4mg was administered every 3-4 weeks, a total of 7 times. Patients were randomized 1:1 to the ZOL group or CT group, according to the presence or absence of lymph node metastasis, estrogen receptor (ER) status, and menopausal status. The primary endpoint was the rate of pCR defined as absence of invasive disease in the breast at surgery. The planned sample size was 180 patients. Results: 188 patients were recruited between March 2010 and April 2012; however 10 patients were excluded from the primary assessment. The overall pCR rate was 14.8% and 7.8% in the ZOL and CT groups, respectively (p=0.160). In the postmenopausal patients, pCR rate was 18.4% and 5.4% in the ZOL and CT groups, respectively (p=0.153). In the triple-negative patients, pCR rate was 35.3% and 11.8% in the ZOL and CT groups, respectively (p=0.225). In the postmenopausal and triple-negative patients, pCR rate was 50.0% and 0% in the ZOL and CT groups, respectively (p=0.077). There was no significant difference in severe toxicity between the two groups. Conclusions: The results of this trial suggest that the addition of ZOL to neoadjuvant CT has potential anti-cancer benefit in patients with postmenopausal and triple-negative breast cancer. Further investigation will be warranted. Clinical trial information: 000003261.
Collapse
Affiliation(s)
- Jun Horiguchi
- Gunma University Hospital, Breast and Endocrine Surgery, Maebashi, Japan
| | | | | | - Takashi Ishikawa
- Department of Breast and Thyroid Surgery, Yokohoma City University Medical Center, Yokohama, Japan
| | | | | | - Seung Jin Kim
- Graduate School of Medicine Oskaka University, Osaka, Japan
| | | | | | | | - Yasushi Shigeoka
- Department of Clinical Oncology, Yodogawa Christian Hospital, Osaka, Japan
| | | | | | - Norio Kohno
- Department of Breast Oncology, Tokyo Medical University Hospital, Tokyo, Japan
| |
Collapse
|
38
|
Yamamoto N, Yamashiro H, Iwata H, Masuda N, Ohtani S, Takahashi M, Yamazaki K, Kato M, Ohno S, Kuroi K, Yamagami K, Morimoto T, Hasegawa Y, Takano T, Kadoya T, Hosoda M, Abe H, Morita S, Yasuno S, Toi M. Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01). J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.613] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
613 Background: The global randomized trials with trastuzumab (H) shows increased cardiotoxicity in patients (pts) with HER2 positive early breast cancer (BC). Safety in Japanese has not been fully evaluated. We evaluated the safety, especially focused on cardiotoxicity, of H adjuvant (adj) therapy in an observational study in Japan (UMIN000002737). Methods: Pts with histopathologically confirmed HER2 positive invasive BC were registered. Women with stage I-IIIC disease who received H as neo-adj and/or adj therapy were eligible. Mean LVEF at 3, 6, 9 and 18 months (M) was evaluated. The time points represent examination on day 60-120, 150-210, 240-330 and 455-635, respectively. Results: A total of 2024 pts were registered from 56 institutes between July 2009 and June 2011. Data of 1875 pts were collected and finalized by September 2012, and 1800 of them were analyzed for safety. The median follow-up was 35 M. The mean age was 54.5 years. Elderly pts ≥60 years were 32.7%. Treatments after surgery were: concurrent chemotherapy (CT) and H in 20.1%, sequential CT and H in 43.5% and H monotherapy in 35.9%. Adverse events (AEs) associated with H were reported in 350 pts (19.4%) and grade (G) 3/4 AEs in 12 pts (0.7%). G 3/4 cardiotoxicity was reported in 7 pts (dysfunction, 4pts; angina, 1 pt; myocardial infarction, 1 pt and heart failure, 1 pt). The mean LVEF at the baseline was 69.4%. Mean LVEF at 3, 6, 9 and 18M were 66.9%, 66.3%, 65.3% and 66.3%, respectively. Compared to the baseline, LVEF decreased with significant difference at all time points (p<0.0001). LVEF decrease ≥10% occurred in 177 pts (during H treatment,130 and after H treatment, 47). Follow-up data were available in 66 pts: 34 pts recovered to the baseline. Mean time to recover was 262 days. The univariate analysis showed using anthracycline (odds ratio 2.312, p=0.003) was the only risk factor for cardiotoxicity. However, elderly, radiation concurrent/sequential treatment with CT and H had no impact. Conclusions: From our study, we found the AE profiles of H were consistent with previously known AEs. We found using anthracycline was the risk factor for cardiotoxicity at the moment. We should carefully follow pts and watch long-term safety. Clinical trial information: 000002737.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Katsumasa Kuroi
- Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
| | | | | | | | | | | | | | - Hajime Abe
- Department of Surgery, Shiga University of Medical Science, Otsu, Japan
| | - Satoshi Morita
- Yokohama City University Medical Center, Kanagawa, Japan
| | | | - Masakazu Toi
- Graduate School of Medicine Kyoto University, Kyoto, Japan
| |
Collapse
|
39
|
Sugie T, Sawada T, Tagaya N, Kinoshita T, Yamagami K, Suwa H, Ikeda T, Yoshimura K, Niimi M, Shimizu A, Toi M. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol 2013; 20:2213-8. [PMID: 23429938 DOI: 10.1245/s10434-013-2890-0] [Citation(s) in RCA: 114] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Indexed: 02/06/2023]
Abstract
PURPOSE To assess the diagnostic performance of sentinel lymph node (SLN) biopsy using the indocyanine green (ICG) fluorescence method compared with that using the blue dye method, a prospective multicenter study was performed. METHODS Patients with T1-3 primary breast cancer without clinical lymph node involvement were included in this study. ICG as a fluorescence-emitting source and indigo carmine as blue dye were injected into the subareolar area. Extracted lymph nodes were examined to identify the first, second, and other SLNs. The identified nodes were classified according to the ICG fluorescence signal and blue dye uptake. RESULTS Ninety-nine eligible patients were included in this study. The ICG fluorescence method identified an average of 3.4 SLNs (range, 1-8) in 98 of 99 patients (detection rate, 99 %). The number of lymph nodes identified by the fluorescence method was significantly higher than that identified by the blue dye method (p < 0.001). SLN involvement was identified in 20 % (20 of 99) of patients, all of whom tested positive for the first SLN. In 16 patients, complete axillary lymph node dissection (ALND) was performed. In 25 % (4 of 16) of these patients, axillary metastases were identified; however, no axillary involvement was found in 8 patients with only one involved node, which was isolated as the first SLN. CONCLUSIONS High rate of SLN detection was achieved using the ICG fluorescence method. The first SLN identified by fluorescence imaging provides an exact indication of the axillary status. Therefore, the ICG fluorescence method provides precise information required to avoid unnecessary ALND.
Collapse
Affiliation(s)
- Tomoharu Sugie
- Department of Breast Surgery, Kyoto University, Kyoto, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Azhim A, Yamagami K, Muramatsu K, Morimoto Y, Furukawa KS, Tanaka M, Fukui Y, Ushida T. The Use of Sonication Treatment to Completely Decellularize Aorta Tissue. IFMBE Proceedings 2013. [DOI: 10.1007/978-3-642-29305-4_522] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
41
|
Saeki T, Takahashi T, Okabe M, Furuya A, Hanai N, Yamagami K, Mandai K, Moriwaki S, Doihara H, Takashima S, Salomon D. Immunohistochemical detection of ribonucleotide reductase in human breast-tumors. Int J Oncol 2012; 6:523-9. [PMID: 21556566 DOI: 10.3892/ijo.6.3.523] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Ribonucleotide reductase (RNR) consists of two non-identical subunits, R1 and R2 and is one of the key enzymes involved in DNA biosynthesis. RNR activity is considerably higher in malignant tumors than in normal tissues in the rat suggesting that RNR may play an important role in the pathogenesis of human tumors. In order to obtain immunological reagents to study the localization and level of expression of RNR in various human tissues, a synthetic peptide containing sequences corresponding to the COOH-terminal region of the human R2 subunit was used to generate rat monoclonal antibodies. The generated rat monoclonal antibodies (IgG) inhibited RNR enzymatic activity purified from murine P388 leukemia cells. These antibodies were used to immunohistochemically examine the distribution of RNR in a small panel of 8 malignant and 4 benign human breast tumors. Positive immunostaining for RNR was observed in the cytoplasm of human breast carcinoma cells in which a specific 44 kDa specific band of R2 subunit was also detected by Western blot analysis. The immunostaining was blocked by preabsorption of the antibody with an excess amount of the synthetic peptide immunogen. In 8 of 8 breast carcinomas, positive immunostaining for the R2 subunit was observed whereas noninvolved, adjacent breast tissue showed no staining with this antibody. In addition, few of the benign breast lesions exhibited staining with this antibody. These data indicate that these antibodies can immunohistochemically detect RNR in frozen or formalin-fixed, paraffin- embedded tissues and that there is a differential expression of RNR between breast tumors and non-involved breast tissue. Immunohistochemical detection of RNR using these antibodies may therefore be useful for the diagnosis of human breast tumors.
Collapse
Affiliation(s)
- T Saeki
- NCI,TUMOR GROWTH FACTOR SECT,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892. KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,TOKYO,JAPAN. KYOWA HAKKO KOGYO CO LTD,PHARMATHEUT RES LABS,SHIZUOKA,JAPAN
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Winchester CL, Ohzeki H, Vouyiouklis DA, Thompson R, Penninger JM, Yamagami K, Norrie JD, Hunter R, Pratt JA, Morris BJ. Converging evidence that sequence variations in the novel candidate gene MAP2K7 (MKK7) are functionally associated with schizophrenia. Hum Mol Genet 2012; 21:4910-21. [DOI: 10.1093/hmg/dds331] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Sugie T, Sawada T, Tagaya N, Kinoshita T, Yamagami K, Suwa H, Yoshimura K, Nimi M, Toi M. 72 Identification of Sentinel Lymph Node Metastasis and Axillary Status in Early Breast Cancer by Indocyanine Green Fluorescence Method. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70140-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Higashiyama H, Yamagami K, Fujimoto K, Koshiba T, Kumada K, Yamamoto M. Open surgical repair using a reimplantation technique for a large celiac artery aneurysm anomalously arising from the celiomesenteric trunk. J Vasc Surg 2011; 54:1805-7. [PMID: 21803520 DOI: 10.1016/j.jvs.2011.05.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2011] [Revised: 05/02/2011] [Accepted: 05/07/2011] [Indexed: 10/17/2022]
Abstract
Celiac artery aneurysms anomalously arising from the celiomesenteric trunk (hepatosplenomesenteric trunk) are rare, with only four patients reported thus far. Surgical intervention for this condition is challenging, particularly when the aneurysm is large and in a retropancreatic location. We report an open repair surgery in a 54-year-old asymptomatic man who presented with a saccular calcified aneurysm (diameter, 4.0 cm) of the celiac artery originating from the celiomesenteric trunk. Our technique involved minimal dissection of the surrounding vessels and complete aneurysm resection, along with revascularization of the hepatic, splenic, and superior mesenteric arteries with a single anastomosis.
Collapse
|
45
|
Sugie T, Sawada T, Tagaya N, Kinoshita T, Yamagami K, Suwa H, Yoshimura K, Sumi M, Toi M. Validation study on the clinical usefulness of the ICG fluorescence method for detecting sentinel lymph node in early-stage breast cancer in comparison with the dye method. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1122] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Azhim A, Yamagami K, Muramatsu K, Morimoto Y, Tanaka M. The use of sonication treatment to completely decellularize blood arteries: a pilot study. Annu Int Conf IEEE Eng Med Biol Soc 2011; 2011:2468-2471. [PMID: 22254841 DOI: 10.1109/iembs.2011.6090685] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We have developed a novel sonication decellularization system to prepare completely decellularized bioscaffolds in a short treatment time. The aim of the study is to investigate the sonication decellularization efficiency and its relation with ultrasonic power output and dissolved oxygen (DO) concentration in different detergent solution. In the study, we used aorta samples to evaluate sonication decellularization efficiency, which assessed treatment duration, sonication power and SDS detergent with/without saline. The treated samples were evaluated histologically by Hematoxylin Eosin (HE) staining and scanning electron microscopic (SEM) photographs. The concentration of DO was monitored to identify the effect of sonication on cavitation-related DO concentration in the solution. From histological results, the sonication decellularization efficiency was better than the other preparation methods. Decellularization efficiency was tended to increase significantly when DO value decreasing after 6 hours of treatment. In conclusion, we conclude that sonication treatment can be used to prepare the complete decellularized scaffolds in short treatment time.
Collapse
Affiliation(s)
- A Azhim
- Frontier R& D Center, Tokyo Denki University, Hatoyama 350-0394, Japan.
| | | | | | | | | |
Collapse
|
47
|
Sugie T, Kassim KA, Takeuchi M, Hashimoto T, Yamagami K, Masai Y, Toi M. Abstract P1-01-12: A Novel Method for Sentinel Lymph Node Biopsy by Indocyanine Green Fluorescence Technique in Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-01-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Sentinel lymph node (SLN) biopsy is the standard method to assess the actual axillary lymph node status in breast cancer. Currently dye techniques, radioisotope techniques or combined techniques are usually used for SLN detection. Recently, near infrared fluorescence imaging has been applied clinically in a breast cancer patient to identify SLN. In this study, the feasibility of SLN biopsy using the indocyanine green (ICG) technique were evaluated.
Methods: The study involved four hundreds eleven patients with clinically node negative early breast cancer who underwent SLN in three institutes. A combination of ICG as a fluorescence emitting source and blue dyes were injected in the subareolar area and lymphatic flows were traced with a charge coupled device camera and a real-time image guided surgery enabled to identify the fluorescence image of SLN after meticulous dissection.
Results: The subcutaneous lymphatic channels were detected precisely in all cases. The identification rate of SLN was 99%, (408/411) with a mean number of 2.3±1.2 (range, 1-9) nodes identified per patient. Only one SLN harvested in 30.1% of patients, two in 29.4%, three in 23.9% and four or more in 15.9% of patients. Thirty nine cases (9.5%) had SLNs involved and all of them were ICG positive and 30 of 39 patients (77%) had one SLN involved.
Conclusions: This ICG fluorescence method is simple and achieves a high SLN identification rate. This technique does not require a facility equipped to use radioisotopes. This means that SLN biopsies could even be performed in a small hospital. Orderly and sequential dissection along the lymphatic flow may provide higher sensitivity compared with the conventional radioisotope method. A direct comparison between the radioisotope and ICG fluorescence methods is now required.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-01-12.
Collapse
Affiliation(s)
- T Sugie
- Kyoto University Hospital, Kyoto, Japan; South Egypt Cancer Institute, Assiut University, Assiut, Egypt; Shinko Hospital, Kobe, Japan; Kobe City Medical Center, General Hospital, Kobe, Japan
| | - KA Kassim
- Kyoto University Hospital, Kyoto, Japan; South Egypt Cancer Institute, Assiut University, Assiut, Egypt; Shinko Hospital, Kobe, Japan; Kobe City Medical Center, General Hospital, Kobe, Japan
| | - M Takeuchi
- Kyoto University Hospital, Kyoto, Japan; South Egypt Cancer Institute, Assiut University, Assiut, Egypt; Shinko Hospital, Kobe, Japan; Kobe City Medical Center, General Hospital, Kobe, Japan
| | - T Hashimoto
- Kyoto University Hospital, Kyoto, Japan; South Egypt Cancer Institute, Assiut University, Assiut, Egypt; Shinko Hospital, Kobe, Japan; Kobe City Medical Center, General Hospital, Kobe, Japan
| | - K Yamagami
- Kyoto University Hospital, Kyoto, Japan; South Egypt Cancer Institute, Assiut University, Assiut, Egypt; Shinko Hospital, Kobe, Japan; Kobe City Medical Center, General Hospital, Kobe, Japan
| | - Y Masai
- Kyoto University Hospital, Kyoto, Japan; South Egypt Cancer Institute, Assiut University, Assiut, Egypt; Shinko Hospital, Kobe, Japan; Kobe City Medical Center, General Hospital, Kobe, Japan
| | - M. Toi
- Kyoto University Hospital, Kyoto, Japan; South Egypt Cancer Institute, Assiut University, Assiut, Egypt; Shinko Hospital, Kobe, Japan; Kobe City Medical Center, General Hospital, Kobe, Japan
| |
Collapse
|
48
|
Sugie T, Kassim KA, Takeuchi M, Hashimoto T, Yamagami K, Masai Y, Toi M. A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast cancer. Cancers (Basel) 2010; 2:713-20. [PMID: 24281090 PMCID: PMC3835100 DOI: 10.3390/cancers2020713] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2010] [Revised: 04/14/2010] [Accepted: 04/22/2010] [Indexed: 02/06/2023] Open
Abstract
We investigated the feasibility of sentinel lymph node (SLN) biopsy using indocyanine green (ICG) technique in 411 patients with early breast cancer at three institutes. ICG, a fluorescence source, and blue dye were injected into the subareolar area to enable real-time image-guided surgery and identification of SLN fluorescence after meticulous dissection. The subcutaneous lymphatic channels were precisely detected in all cases. SLN identification rate was 99% (408/411) with a mean of 2.3 nodes identified per patient. Thirty-nine cases (9.5%) had SLNs involved and all of them were ICG positive. Thus, the ICG technique has a high SLN identification rate comparable with that of the radioisotope method.
Collapse
Affiliation(s)
- Tomoharu Sugie
- Department of Breast Surgery, Kyoto University Hospital, 54 Kawara-cho Shogoin, Sakyo-ku Kyoto 606-8507, Japan; E-Mails: (M.T.); (M.T.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +81-751-3660; Fax: +81-75-751-3616
| | - Kassim Abdelazeem Kassim
- Department of Breast Surgery, Kyoto University Hospital, 54 Kawara-cho Shogoin, Sakyo-ku Kyoto 606-8507, Japan; E-Mails: (M.T.); (M.T.)
- Surgical Oncology Department, South Egypt Cancer Institute, Assiut University, El-Methaq St., Mansheit El-Omara square, Assiut, Egypt; E-Mail: (K.K.)
| | - Megumi Takeuchi
- Department of Breast Surgery, Kyoto University Hospital, 54 Kawara-cho Shogoin, Sakyo-ku Kyoto 606-8507, Japan; E-Mails: (M.T.); (M.T.)
| | - Takashi Hashimoto
- Department of Surgery, Shinko Hospital, 1-4-47, Wakihama-cho, Chuo-ku, Kobe 651-0072, Japan; E-Mails: (T.H.); kazu.yama.- (K.Y.)
| | - Kazuhiko Yamagami
- Department of Surgery, Shinko Hospital, 1-4-47, Wakihama-cho, Chuo-ku, Kobe 651-0072, Japan; E-Mails: (T.H.); kazu.yama.- (K.Y.)
| | - Yoshikazu Masai
- Department of Surgery, Kobe City Medical Center General Hospital, 4-6 Minatojima Nakamachi Chuo-ku, Kobe 650-0046, Japan; E-Mail: (Y.M.)
| | - Masakazu Toi
- Department of Breast Surgery, Kyoto University Hospital, 54 Kawara-cho Shogoin, Sakyo-ku Kyoto 606-8507, Japan; E-Mails: (M.T.); (M.T.)
| |
Collapse
|
49
|
Yamagami K, Hashimoto T, Yamamoto M. The efficacy of sentinel lymph node and lymphatic tracts detection using fluorescence navigation with indocyanine green in breast cancer: An analysis of 410 patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Shinohara H, Okamoto S, Nishitai R, Shirakata Y, Itoi K, Yamagami K, Taki Y, Yamamoto M, Mizuno Y. [A phase I study of intraperitoneal plus intravenous paclitaxel against gastric cancer with peritoneal dissemination (HGCG 0301)]. Gan To Kagaku Ryoho 2006; 33:2027-31. [PMID: 17197747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
The safety of the intraperitoneal (ip) plus intravenous (iv) paclitaxel against gastric cancer with peritoneal dissemination was evaluated on a phase I dose escalation trial. Patients were treated with ip paclitaxel administered in 500 ml of normal saline before closing the abdomen, using the following dose levels: level 1, 50 mg/m(2); level 2, 60 mg/m(2); level 3, 70 mg/m(2); and level 4, 80 mg/m(2), followed by iv infusion of the same doses of paclitaxel on days 14 and 21. Twelve patients were enrolled in this study: 7 underwent reduction surgery,while 5 had only a laparotomy. ip therapy was well tolerated, and did not bring about any postoperative complications even in patients who underwent gastrectomy. Although multiple NCI/CTC grade 1 toxicities and grade 2 anemia (4 of six patients at dose levels 2 and 3) were observed, there was no dose-limiting toxicity. The overall median survival time was 316 days, and that for patients who underwent gastrectomy was 413 days. Paclitaxel at a dose of 80 mg/m(2) can be delivered by the operative ip route with acceptable toxicity profile.
Collapse
|